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A b st r a c t
Prostate cancer is the most commonly diagnosed malignancy in males in the United States and its progression depends on active androgen 
receptor (AR) signalling. Androgen deprivation therapy provides palliation 
but not cure, and the disease progresses to castration-resistant prostate cancer 
(CRPC). The taxanes represent the most effective class of anti-tumour agents 
that improve survival in CRPC patients. However, their benefits are transient 
and nearly all patients eventually progress. Understanding the molecular 
basis of taxane activity in prostate cancer is imperative for establishing 
successful treatment of this disease.
The work in this study shows that AR associates with microtubules 
and that taxanes impair the ligand-induced nuclear accumulation of AR. 
Furthermore, co-immunoprecipitation assays and confocal microscopy 
revealed that AR trafficking towards the nucleus occurs along microtubules 
with the aid of the dynein motor protein.
These results have been extended to two clinically relevant, ligand- 
independent AR splice variants, ARv567 and AR-V7. Live cell imaging 
experiments showed that ARv567 is dependent on microtubules in the same 
way as the full-length receptor, as pretreatment with microtubule-targeting 
drugs abrogated nuclear accumulation of both. However, this does not apply 
to the AR-V7 variant, which is not under microtubule control and remains 
insensitive to taxane treatment. Furthermore, the results show that ARv567, 
but not AR-V7, associates with microtubules as evidenced by microtubule co­
sedimentation assays and requires dynein for its nuclear translocation.
In addition, deletion mutants of the AR show that the DNA binding 
domain and hinge region of the receptor are important for microtubule 
binding.
Taken together, these data suggest that inhibition of AR nuclear 
accumulation underlies, in part, the activity of taxanes in CRPC revealing a 
new mechanism of action for this class of drugs and that the presence of AR 
splice variants may determine the clinical efficacy of taxane chemotherapy.
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Preface
Preface
In  2012, about six hundred thousand Americans, and more than eight million people worldwide will die of cancer. According to the World 
Health Organisation this number is expected to grow 75% to 13.1 million by 
2030, making cancer a leading cause of death worldwide and nearly doubling 
the death rate in some of the developing countries. In the United States, one in 
three women and one in two men will develop cancer during their lifetime. 
Furthermore, since 2001, cancer has surpassed heart disease to become the 
most common cause of death in individuals under the age of 85. Therefore, 
countries worldwide, will have to take account of the specific challenges they 
will face and prioritise targeted treatments, emphasising the need for 
prevention measures, early detection systems and effective treatment 
programs.
Since the use of mustard gas to cure lymphomas in the early 1940's, 
many other drugs have been developed to treat cancer. Natural product 
agents have always been attractive targets for drug development, since plants 
growing in harsh, exposed environments, produce a plenitude of natural 
chemical compounds which can provide broad spectrum health benefits 
against cancer and other chronic human 
diseases. In 1958, the National Cancer Institute 
initiated a study to screen some 35,000 plants for 
anticancer activity. Arthur S. Barclay was one of 
several Department of Agriculture botanists 
who took part in the study. After being charged 
with collecting plant samples, Barclay filled a 
bag with traces from Pacific yew trees in a forest 
near Mount St. Helens in the Pacific Northwest 
region of the United States, not knowing that 
history was about to be made.
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Preface
In 1971, when Monroe E. Wall and his coworker Mansukh C. Ward 
isolated and purified the active ingredient from extracts of the tree's bark, its 
importance became significant and paclitaxel (Taxol) -the pioneer of one of 
the most effective anti-cancer drug family (taxanes) clinically available- 
became one of the all-time best-selling cancer-treatment drugs.
Despite the main question -how does paclitaxel kill cancer cells- having 
been answered by Susan B. Horwitz in the late 1970zs and the discovery of 
two more paclitaxel analogues, docetaxel (Taxotere) and cabazitaxel 
(Jevatana), taxane drug resistance represents a major obstacle to improving 
the overall response and survival of cancer patients to this class of molecules. 
Serendipitous discovery of chemotherapeutic compounds in the 1950/s and 
1960/s has now given way to targeted therapies based on molecular 
alterations of specific tumours, leading to chemotherapy customisation. In the 
case of the taxanes, it is imperative to understand the pathways that 
microtubules, the target of taxanes, control in order to understand patients' 
differential response to different taxanes or why they work for some tumour 
types but not all. Understanding how a cancer cell becomes resistant to a drug 
that inhibits the precise target that allows for its survival will provide the 
understanding necessary to design novel drugs with improved antitumour 
efficacy.
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In t r o d u c t io n
Introduction
1.1 A clinical overview of prostate cancer
Prostate cancer, the second most common cause of cancer related deaths in men in the United States after lung cancer (Siegal et al, 2012), is a 
complex, multifactorial disease. It is predominantly a disease of elderly men; 
however, the aetiology of prostate cancer is insufficiently understood. An 
understanding of the genetic and molecular basis of the development and 
progression of prostate cancer has important implications for diagnosis and 
prognosis, as well as for the prediction of the response to therapy.
The presence of the prostate is universal in mammals; w hen 
comparisons are made between species, the prostate is marked by variations 
in its anatomy, biochemistry and pathology (Frick and Aulitzky, 1991). The 
prostate is an exocrine gland that secretes enzymes, amines, lipids and metal 
ions, essential for the normal function of the spermatozoa. In humans, the 
prostate surrounds the urethra at the base of the bladder. The epithelial cells 
provide secretions that are released through ducts into the urethra to form a
5
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major component of the seminal plasma of the ejaculate, which carries sperm 
(Frick and Aulitzky, 1991). The prostate is stimulated to grow and is 
maintained in size and function by the presence of serum testosterone. The 
normal adult prostate gland is remarkable for the heterogeneity of its tissue 
components, comprising histologically distinctive tissues arranged in various 
zones, these being the glandular epithelial and the anterior fibromuscular 
stroma (Sommer et al, 1986). The glandular part is composed of a large 
peripheral zone and a small central zone which together constitute 95% of the 
gland (Figure 1.1). The rest is composed of the transition zone and the peri­
urethral glands. The transition zone consists of two equal portions of 
glandular tissue lateral to the urethra in the midgland (Figure 1.1). Most 
prostate cancers retain some glandular structure and are therefore classified 
as adenocarcinoma (Schulz et al, 2003). Three types of cells make up the 
glandular epithelium: basal, luminal secretory epithelial cells and
neuroendocrine. The luminal cells secrete components of prostatic fluid, 
including prostate-specific antigen (PSA), a serine protease, in a hormone- 
dependent manner and express the androgen receptor (AR) (Feldman and 
Feldman, 2001). In addition, extensive apoptosis of luminal cells as well as a 
lower percentage of basal cells has been observed upon androgen withdrawal 
(Wang et al, 2009). They are also believed to be the cells of origin of hum an 
prostate cancer, since pathologists diagnose the disease based on the absence 
of basal cell markers (Goldstein et al, 2010).
The earliest tumour precursor detected histologically is prostatic 
intraepithélial neoplasia (PIN), which is characterised by thickening of the 
epithelial layer and loss of the basal and secretory layers. Rates of cell 
proliferation remain low in PIN and in prostate carcinomas during much of 
their development (Schultz et al, 2003).
6
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Central zone
Amener fibromuscular svoma
Peripheral zone
Figure 1.1 Zonal anatomy of the human prostate. The different components of the prostate 
gland are shown. The transition zone comprises only 5% of the glandular tissue and the 
remaining 95% is comprised of the peripheral zone and the central zone, which is traversed 
by the ejaculatory ducts (McNeal, 1968).
While many prostate carcinomas retain a quiescent growth pattern 
without manifesting any symptoms, an estimated third become locally 
invasive possibly due to the multifocal pattern of the disease in which more 
than one foci of carcinogenic cells can be found in a prostate, causing it to 
spread beyond the tissue and metastasising to local lymph nodes and distal 
organs, most frequently bone, liver and lung (Schultz et al, 2003). Tumour 
grading of prostate cancer is a fundamental determinant of disease biology 
and progression and as a consequence of the heterogeneity of the disease the 
Gleason scoring system is the most widespread method of prostate cancer 
tissue grading. It considers the degree of tissue disorganisation in the two 
main components of the carcinoma as originally described and developed by 
Dr. Donald Gleason in 1974 (Gleason and Mellinger, 1974). In order to grade 
tumours, microscopic examination of biopsies is carried out and a number 
between 1 and 5 is assigned based on how distorted the cells appear. A sum 
of the primary grade, representing the majority of the tumour, and a
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secondary grade, assigned to the minority of the tissue is given as a total score 
between 2 and 10. Increased Gleason scores indicate more aggressive tumours 
and worse patient prognosis.
Currently, an increasing number of prostate cancers are detected 
through elevated serum PSA levels, which can increase in prostate cancer up 
to lO^-fold (Lilja et al, 2008). Many cases are detected by PSA levels in the 2.5- 
10 ng /m l range, which are further confirmed by histology of biopsies. PSA 
detection is very sensitive, albeit imperfect, since non-cancer reasons for an 
elevated PSA include prostate enlargement, inflammation and infection.
Presently, approximately 85% of newly diagnosed prostate cancers are 
localised to the prostate, with the remainder representing invasive or 
metastatic disease (Cooperberg et al, 2004). Some of the recognised treatment 
options for early-stage disease include surgery, radiation therapy and active 
surveillance carried out by PSA testing, prostate needle biopsies and 
ultrasounds (Harris et al, 2009).
Prostate cancer has been identified as an androgen-sensitive disease 
since the fundamental work of Huggins and Hodges in 1941 (Huggins and 
Hodges, 1941). It is dependent on androgen stimulation mediated by the AR, 
a member of the steroid hormone receptor family of ligand-dependent 
nuclear receptors (Taplin et al, 1999). Androgens acting through the AR have 
important effects throughout life, ranging from the effects on pubertal 
development to the genesis of prostatic hyperplasia, leading to prostate 
cancer (Gelmann, 2002). Therefore, for many men with advanced local or 
metastatic disease, androgen deprivation is a critical component of therapy, 
either alone or in combination with surgery or radiation therapy (Harris et al, 
2009).
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The molecular genetics of prostate cancer are poorly understood. No 
major predisposition genes for prostate cancer have been detected, affirming 
its heterogeneous nature (Visakorpi, 2003). This suggests that the 
predisposition to prostate cancer may involve multiple genes. Molecular 
analyses have shown that multiple chromosomal loci of susceptibility exist 
even though the susceptibility genes for most of these regions remain 
unknown (Visakorpi, 2003). Furthermore, studies done on various métastasés 
in the same patient showed that these were clonally related (Mehra et al, 2008; 
Liu et al, 2009), indicating that advanced prostate cancer may arise from the 
selective advantage of individual clones during cancer progression or as a 
consequence of therapeutic interventions such as androgen deprivation, 
which may select for the survival of cells with a major malignant potential 
(Shen and Abate-Shen, 2010).
During the development and progression of cancer, tumour suppressor 
genes and oncogenes often undergo loss of function and gain of function, 
respectively, predominantly through alterations in the genomes of cells 
(Dong, 2006). These genomic alterations not only include gene mutation, but 
can also include changes in the copy number of genes as well as chromosomal 
translocations. A small portion of prostate cancers have a hereditary factor 
and some genes with germline mutations in hereditary cancer have been 
identified. Furthermore, epigenetic mechanisms, such as DNA méthylation 
can also cause molecular alterations during carcinogenesis (Dong, 2006). In 
addition, chromosomal rearrangements and copy number gains and losses, 
including fusions in the ETS transcription factor family member, the ETS- 
related gene (ERG), phosphatase and tensin homolog (PTEN) loss and AR 
amplification, have been identified as a result of characterisation of the 
prostate cancer transcriptome and genome (Grasso et al, 2012).
9
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In addition, mutations in key oncogenes and tumour suppressor genes 
have been detected in prostate cancer cells. p53 and PTEN are among the 
established tumour suppressor genes to be clearly involved in the progression 
of prostate cancer since losses of chromosome 17p and 10q, where they are 
located respectively, have been found to occur with moderate frequencies in 
advanced cancers (Schulz et al, 2003). Moreover, a high rate of mutations and 
deletions in PTEN has been detected in cell lines as well as in metastatic 
lesions of prostate cancer (Vlietstra et al, 1998). Mutations in the p53 gene are 
rare in early, prostate cancer, whereas in advanced prostate carcinomas they 
are found in about 20-25% of cases, suggesting a role for the accumulation of 
mutated p53 in the progression of a subset of prostate cancers (Bookstein et al,
1993). Mutated p53 proteins with novel, oncogenic properties that result in 
the protein having a long half-life, accumulate in the cell nuclei and are 
associated with poor prognosis (Visakorpi et al, 1992). Furthermore, mutation 
of p53 impairs genomic stability, leading to genomic amplification of the AR 
gene during hormone therapy (Dong, 2006), suggesting that p53 gene 
mutation is more likely a late event in the progression of prostate cancer and 
associated with advanced stage and the transition from androgen-dependent 
to androgen-independent growth. Similarly, the loss of the homeobox gene 
NKX3.1, which maps to 8p21 and encodes a transcription factor almost 
exclusively expressed in the prostate has also been detected in high-grade PIN 
lesions, suggesting it is a prostate-specific tumour suppressor gene (Bhatia- 
Gaur et al, 1999). Moreover, up to 50% of prostate cancers harbour fusions 
between the transmembrane protease serine 2 (TMPRSS2) and the oncogenic 
ETS transcription factor, ERG (Tomlins et al, 2007). TMPRSS2 is an androgen 
regulated gene whose expression has been localised to prostate basal cells and 
to prostate carcinomas and therefore is thought to be involved in prostate 
carcinogenesis (Lin et al, 1999). ERG is a transcription factor key in embryonic
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development, cell proliferation and differentiation as well as in inflammation 
and apoptosis. Interestingly, recent studies have indicated that prostate 
cancer patients with the TMPRSS2-ERG gene fusion have a higher risk of 
disease recurrence (Barwick et al, 2010). TMPRSS2-ERG disrupts AR 
signalling, which may provide a malignant selection pressure contributing to 
recurrent tumours with AR amplification that could exert a selective pressure 
for the development of prostate cancer that is resistant to the current 
therapies. (Yu et al, 2010).
Rather than being due to mutations in specific genes that result in 
disease, genetic susceptibility to prostate cancer may result from 
polymorphisms in genes associated with metabolic enzymes or sex hormone 
activation (Taplin and Ho, 2001) that are prevalent in the population. The 
most widely studied polymorphic gene is the AR, which contains 
polymorphic CAG and GGN repeats encoding glutamine and glycine repeats 
respectively in its N-terminal transcriptional activation domain. Overall, in 
vitro analyses have suggested that the length of the CAG repeat is inversely 
related to the transcriptional activity of the AR, with 40 or more repeats being 
associated with androgen insensitivity (Chamberlain et al, 1994). Polymorphic 
differences or mutational changes in poly-glutamine length may affect cancer 
risk and clinical progression, as the majority of prostate cancers are AR 
positive. Shorter repeats seem to be associated with early onset and the 
occurrence of a more aggressive prostate cancer, suggesting that early 
tumourigenesis is dependent on a more active AR (Irvine et al, 1995). The 
other exon 1 polymorphism, the GGN repeat, may influence prostate cancer 
risk but its functional significance still remains controversial.
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1.2 Androgen receptor
1.2.1 Overview and structure
The androgen receptor was first described in 1969 (Fang et al, 1969) and 
cloned in 1988 (Chang et al, 1988). The AR gene is located on chromosome X at 
Xqll-12 and therefore is single-copy in males. Complete loss of function of 
the AR in men, as a result of mutations or abnormal glutamine repeats in the 
receptor, results in complete androgen insensitivity syndrome, which 
manifests as a sterile, female-like phenotype (Wisniewski et al, 2000). The AR 
gene contains 8 exons and spans a length of approximately 100 kb of DNA 
(Lubhan et al, 1988). The cDNA sequence of the human AR is composed of 
2763 nucleotides, encoding a protein of 919 amino acid residues with a 
calculated molecular mass of about 100 kDa (Trapman et al, 1988). Consistent 
with its widespread effects, AR is found in cells of tissues other than the 
sexual organs and, except for the spleen, it is difficult to find a tissue that does 
not express some amount of AR (Gelmann, 2002).
The AR is a transcription factor belonging to the steroid hormone 
family of nuclear receptors, which exist as homo- or heterodimers (Olefsky, 
2001). Nuclear receptors regulate a vast amount of physiological functions, 
such as homeostasis, development and metabolism and are present in both 
normally differentiated cells as well as in cancerous cells (Robinson-Rechavi et 
al, 2003). The ultimate goal of a nuclear receptor is to activate transcription 
upon binding of its ligand, which must traverse the plasma membrane to bind 
to the receptor. Consistent with other steroid receptor proteins, the full-length 
AR protein contains four functional domains: the N-terminal tr ans activation 
domain (NTD), a central DNA-binding domain (DBD), a C-terminal ligand- 
binding domain (LED) and a hinge region connecting the DBD and LBD 
(Gelmann, 2002) (Figure 1.2). The structurally distinct NTD, encoded by a
12
Introduction
q ll-1 2
X chromosome Ç
Intron size (kb) >20 >15 26
Exon size (bp) 1613 152 117 288 145 131 158 155
1
(Gln)lfcu (Pro), (Gly),
DNA-binding
Transcription Regulation Hinge Ugand-binding
Amino Add 1 537 Zn 20*626 919
Figure 1.2 Genomic organisation of the AR gene. The AR gene spans more than 100 kb and
is comprised of eight exons shown in the second panel. Exon 1 is the largest exon required for 
transactivation functions and exons 2-8 encode a DNA-binding domain, hinge region and 
ligand-binding domain (Gelmann, 2002).
single large exon (exon 1) comprises almost half of the AR molecule and 
harbours one of the two transcription activation sites, also known as 
activation function 1 (AF-1). This region contains sequence information for at 
least two critical features: (i) to optimise the transactivation capability of the 
receptor and (ii) to specify gene recognition in the transcriptional regulation. 
This domain may also represent the most immunogenic part of the protein as 
it has the least conserved amino acid sequences among members of the 
nuclear receptor superfamily (Hirawat et al, 2003). It has several 
homopolymeric amino acid stretches, including a polyglutamine (CAG), a 
poly glycine (GGN) and polyproline (CCN) repeat (Chamberlain et al, 1994). 
The length of these segments varies among healthy individuals (9-33 
glutamine residues), indicating that the AR protein is polymorphic and the 
variation of this repeat can be used as a marker for the AR gene and as an  X- 
chromosome marker (Brinkmann and Trapman, 2000). Exons 2 and 3 encode 
the DBD, which contains two zinc fingers essential for androgen-response 
element recognition. It is the best conserved region among hormone 
receptors. At the end of the DBD, and within the hinge region, encoded by the
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proximal region of exon 4, is the AR nuclear localisation signal (NLS) (aa 617- 
635) that directs the AR to the cell nucleus (Cutress et al, 2008). The C-terminal 
LBD is encoded by part of exon 4 and entire exons 5-8. The LBD (253 residues) 
is involved in receptor dimérisation, is highly hydrophobic and harbours the 
second ligand-dependent activation function site (AF-2) (Brinkmann and 
Trapman, 2000).
The crystal structure of AR's LBD has been determined in complex 
with its cognate hormone revealing a conserved core of 12a-helices (HI to 
H12) and a short two-stranded antiparallel |3-sheet (SI and S2), arranged into 
a three-layered sandwich fold (Bourguet et al, 2000). This arrangement 
generates a mostly hydrophobic cavity in the lower half of the domain into 
which hydrophobic hormones are bound. The ribbon structure of the AR 
bound to its hormone is illustrated in Figure 1.3. In all hormone-bound LBD 
structures, the ligand-binding cavity is sealed by helix H12. This conformation 
is specifically induced by the binding of hormones or synthetic agonists and is 
referred to as the /z active conformation" because it favours the recruitment of 
transcriptional coactivators (Nahoum and Bourguet, 2007).
Figure 1.3 Ribbon diagram of the AR ligand binding domain bound to its ligand DHT. The
AR LBD shown in green and grey ribbon and DHT in yellow and red carbons and oxygens 
(Nahoum and Bourguet, 2007).
14
Introduction
1.2.2 Androgen receptor activity
Testosterone and 5a-dihydrotestosterone (DHT) are the two major androgens 
in men; testosterone being present mainly in the circulation, and DHT being 
the primary androgen in prostatic tissue (Harris et el, 2009). The Ley dig cells 
of the testis produce 90-95% of circulating testosterone, with the remaining 5- 
10% synthesised in the adrenal glands (Labrie, 2004). Testosterone circulates 
in the blood, where it is bound to albumin and sex-hormone-binding globulin 
(SHBG), with a small fraction of 2-3% existing in the free form. Testosterone is 
lipophilic and is thus able to freely diffuse into target cells of organs such as 
the prostate, where it is converted to the more potent intracellular androgen, 
DHT by the two isoforms of 5cr-reductase, S5A1 and S5A2 (Harris et al, 2009). 
The majority of DHT, about 75%, is produced in tissues such as the prostate 
and skin with the remaining 25% of circulating DHT produced in the testis 
(Imamoto et al, 2008). DHT binds the AR in a more stable manner compared 
with testosterone, leading to a 10-fold increase in transcriptional activation, 
making DHT the primary ligand and effector of AR-mediated signalling 
(Imamoto et al, 2008; Askew et al, 2007). In the absence of hormone, the 
receptor is located in the cytoplasm and associated with heat shock protein 
(HSP) complexes, which maintain the AR in a conformation capable of 
binding hormone and protect AR from proteolysis. Binding of hormone 
induces a conformational change in the AR that leads to dissociation from the 
heat shock proteins and receptor phosphorylation, in part mediated by 
protein kinase A (Nazareth and Weigel, 1996). Upon ligand interaction, the 
AR homodimerises, undergoing phosphorylation and the ligand-receptor 
complex translocates to the nucleus where it binds to androgen-response 
elements (AREs) in the promoter regions of target genes involved in cell cycle 
regulation and proliferation (Feldman and Feldman, 2001; Taplin, 2007;
15
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Mostaghel et al, 2009) (Figure 1.4). Binding of the AR ligand complex to the 
AREs leads to recruitment of coactivators, such as the androgen receptor 
associated coregulator 70 (ARA70) to the target gene promoter. These 
coactivators are able to remodel the chromatin by histone acétylation and 
allow for other transcription factors to bind to the promoter region (Jenster,
1999). The coactivators then recruit basal transcription factors to assemble a 
stable preinitiation complex. This effect leads to increased rates of 
transcription initiation by RNA polymerase II (Jenster, 1998). Corepressors 
that bind the AR complex also modulate the genomic actions of AR by 
preventing its interaction w ith the general transcription apparatus (GTA) 
through binding to histone deacetylases (HDACs), leading to transcription 
repression. A change in the ratio coactivator/corepressor may modify AR 
sensitivity to hormone binding. Among them, the coactivator p300 bridges the 
transcriptional machinery of AR and the coactivator family pl60 modifies 
chromatin structure (Mellado et al, 2009). In addition to androgens, growth 
factors such as insulin-like growth factor-I (IGF-1), keratinocyte growth factor 
(KGF) and interleukin-6 (IE-6) are also able to increase the transcription of an 
AR-responsive gene (Hirawat et al, 2003). Activation or repression of target 
genes leads to biological responses such as growth, survival and the 
production of PSA (Feldman and Feldman, 2001) (Figure 1.4).
The nuclear import of the AR is crucial for its function. Its import into 
the nucleus is mediated by the nuclear import receptor, importin-a, that 
recognises and binds to the specific NLS motif on the AR. The interaction 
between AR and importin-a has been shown to be a direct interaction 
determined by the crystal structure of the binding interface of importin-a-AR­
NES (Cutress et al, 2008). Furthermore, heat shock proteins, such as Hsp90,
16
Introduction
Testosterone
5a-reductase
Cytoplasm HSPLigand
binding AR
Dimerization and 
phosphorylation
HSP
AR
C ^-C hrO -#
f AR AR ) Androgen-responsive cell
Coactivator
recruitment
GTADNA ( 
binding
AR AR ARA70
Target gen e activation
Androgen-response
element
tPSA)  ( tGrowth) ( (Survival 
Biological responses ,Nucleus
Figure 1.4 Androgen action. Testosterone circulates in the blood bound to albumin and 
SHBG with a small fraction circulating free. Free testosterone enters prostate cells and is 
converted to DHT by the enzyme 5a-reductase. Binding of DHT to the AR causes dissociation 
from heat shock proteins (HSPs) and induces receptor phosphorylation. The AR dimerises 
and binds to androgen-response elements in the promoter regions of target genes. 
Coactivators (such as ARA70) and corepressors also bind the AR complex, facilitating or 
preventing, respectively, its interaction with the general transcription apparatus (GTA). 
Modulation of target genes leads to biological responses including growth, survival and the 
production of PSA (Harris et al, 2009).
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also play a role in the import of AR since dissociation of Hsp90 from AR, 
following conformational changes in the LBD induced by ligand binding, 
facilitates greater exposure of the hinge regions of the steroid receptors since 
Hsp90 normally masks the NLS site (Georget et al, 2002; Kuil et al, 
1995).Importin-a acts as an adaptor protein to the nuclear transport factor 
importin-p, and after recognising the cargo NLS, the importin-a-importin- 
Picargo complex moves through nuclear-pore complexes (NPCs) into the 
nucleus where it is dissociated by the Ras family GTPase Ran (Cutress et al, 
2008). Importins have a high affinity for RanGTP, and the direct binding of 
RanGTP to the importin receptor in the nucleus promotes the dissociation of 
its cargo and thus the AR is released into the nucleoplasm (Steggerda and 
Paschal, 2002).
Other molecules that are likely to participate in the intracellular 
movement of AR are the actin-binding protein filamin, a 280 kDa component 
of the cytoskeleton and the protein p-catenin, a major component of the Wnt 
signalling pathway (Clevers, 2006). Studies on filamin-deficient cells showed 
that these cells displayed a failed nuclear import of liganded AR (Ozanne et al,
2000) while in studies where AR and p-catenin were coexpressed, both AR 
and p-catenin migrated to the nucleus with the same time progression upon 
stimulation of the Wnt pathway (Mulholland et al, 2002).
1.3 Androgen deprivation therapy for the treatment of prostate 
cancer
Since androgens have a critical role in driving prostate cancer growth, 
physicians have utilised androgen deprivation therapy (ADT) to achieve 
drastic reductions in the rates of testicular androgen synthesis and levels of
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circulating androgens, thereby minimising AR ligand availability and 
subsequent AR-mediated proliferative effects on the prostate. Historically, 
circulating testosterone levels have been used to assess the efficacy of 
androgen depletion. Common methods of ADT include orchiectomy or 
medical castration via the chronic administration of gonadotropin-releasing 
hormone (GnRH) agonists, which prevent the testicles from receiving 
messages to make testosterone. Other medical approaches include oestrogen 
therapy, which also results in impaired androgen production and castrate 
levels of circulating testosterone. Furthermore, anti-androgens that work by 
blocking the AR (such as hydroxyflutamide or bicalutamide) through binding 
to the C-terminal ligand binding domain of the receptor (Thompson, 2010) are 
used in combination with GnRH agonists.
Some of the adverse effects associated with ADT include sexual 
dysfunction, muscle atrophy, osteoporosis, hot flushes, fatigue, gynecomastia, 
anaemia and in some patients, depression and cognitive dysfunction, all 
having a direct impact on quality of life (Seruga and Tannock, 2008). 
Moreover, ADT can also induce the metabolic syndrome, which could 
account for the increased incidences of diabetes and cardiovascular morbidity 
and mortality associated with ADT (Michaelson et al, 2008).
ADT prolongs overall survival, with the majority of cancers (85%) 
having an initial favourable response to hormone therapy. Furthermore, it has 
been shown to be an effective therapy in bone and soft tissue metastasic 
disease, in addition to relieving bone pain and suppressing PSA levels in 80- 
90% of patients with metastatic prostate cancer. Although a positive initial 
response to therapy is common, ADT in metastatic disease is considered 
palliative, as disease progression occurs at a median of 2-3 years, with a 
subsequent expected survival of 16-18 months from the time of progression
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(Pienta and Bradley, 2006). The effects of ADT are limited by the development 
of castration-resistant prostate cancer (CRPC). CRPC is believed to emerge 
after genetic and /o r epigenetic changes in prostate cancer cells rendering 
them insensitive to ADT and allowing the prostate cancer cells to grow 
despite castrate levels of testosterone (Thompson, 2010).
1.4 Biology of castration-resistant prostate cancer
Castration-resistance occurs when surviving prostate cancer cells grow 
despite low or absent testosterone levels, imparting a clonal selection for these 
androgen-independent cells (Petrylak, 2003). Both cell culture and clinical 
studies show that the AR plays a key role in the growth and survival of 
CRPC, a lethal form of the disease, suggesting that AR remains a major target 
for the treatment of CRPC. Hormone-independent progression is typically 
characterised by increases in serum PSA levels, suggesting that an active AR, 
in the absence of normal circulating levels of androgens, is responsible for 
PSA expression.
Several mechanisms that enhance AR signalling in an androgen- 
depleted environment have been shown: (i) increased local synthesis of 
androgens; (ii) AR point mutations that allow activation by low androgen 
levels or non-andro genic ligands; (hi) AR gene amplification or 
overexpression; (iv) crosstalk with cytokines and growth factors and (v) 
alterations in the balance between AR cofactors and corepressors implicated 
in ligand-independent activation of AR signalling (Feldman and Feldman,
2001) (Figure 1.5).
Intra-tumoural androgens may come from an adrenal source or be 
synthesised de novo within the tumour. Over-expression of enzymes key to
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androgen synthesis (FASN, HSD3B1, HSD3B2, CYP17A1, AKR1C3 and 
HSD17B3) has been observed in metastatic hormone-resistant tumours, 
supporting the de novo synthesis of androgens in tumour tissue (Montgomery 
et ah 2008).
AR mutations are present in about 10-20% of prostate cancer patients 
depending on antecedent exposure to compounds, which can apply selective 
pressure for AR mutations (Taplin and Balk, 2004). This percentage of 
mutations is seen more often in patients with hormone-independent disease 
compared to early-stage prostate cancer and in metastasis compared to 
primary tumours, suggesting that the wild-type AR signal might be 
implicated in early prostate cancer progression while AR mutations confer a 
growth advantage to cells during progression (Mellado et al, 2009). Point 
mutations of the AR can also result in non-specific ligand activation such that 
a mutated AR can be activated by non-steroidal ligands such as anti­
androgens. Mutations in the AR were first described in the prostate cancer 
cell line, lymph node carcinoma of the prostate (LNCaP) at codon 877 (Thr to 
Ala) (Taplin, 2007). Importantly, this mutation resulted in AR being 
stimulated by hormones other than androgens, such as progesterone, 
oestradiol as well as by the anti-androgens cyproterone acetate, nilutamide 
and hydroxyflutamide (Veldscholte et al, 1990). All AR mutations that have 
been associated with human diseases, including prostate cancer, have been 
recorded in a database (Gottlieb et al, 2004). It is unclear how many other 
mutations use the same promiscuous receptor mechanism and allow prostate 
cancer cells to become androgen independent. However, the majority of 
mutations reported occur in the LBD (Gelmann, 2002), and most of the 
mutations that have been identified result in a receptor that is more sensitive 
to its ligand, can be activated by other steroid hormones or by the specific
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Figure 1.5 Overview of the mechanisms associated with continued signalling through the 
androgen-signalling axis despite castration in prostate cancer. (1) Intra-tumoural 
steroidogenesis contributes to synthesis of testosterone and DHT, leading to constant tissue- 
level androgens despite castration. (2) Mutations in the AR allowing leading to 
hypersensitisation of the receptor by low-level androgens or alternate ligands. (3) AR 
amplification, which increases its abundance. (4) Ligand-independent activation of AR 
through cross-talk with other pathways. (5) Changes in the balance of coactivators and 
corepressors, which augment AR activity. (6) Pathways bypassing AR activity such as Bcl-2 
upregulation. Abbreviations: AKT, akt serine/threonine kinase; AR, androgen receptor; 
DHEA, dehydroepiandrosterone; DHT, dihydrotestosterone; ERK, extracellular signal- 
regulated kinase; P, phosphorylated residues; PI3K, phosphoinositide 3-kinase; PTEN, 
phosphatase and tensin homolog (Harris et al, 2009).
antiandrogens used in clinical management of the disease (Scher et al, 2004; 
Gottlieb et al, 2004).
In addition to the presence of AR gene mutations, AR gene 
amplification which results in increased AR expression, has been reported for 
33% of patients with CRPC (Ford III et al, 2003) but is present at very low rates 
(1-2%) in those with primary prostate cancer (Visakorpi et al, 1995; Bubendorf 
et al, 1999), indicating that AR amplification, is involved in the development
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of CRPC. AR gene amplification in patients was associated with an increased 
mRNA expression and augmented levels of AR protein (Edwards et al, 2003). 
However, it has also been shown that patients with CRPC may have AR over­
expression at the mRNA and protein levels in the absence of AR 
amplification, potentially occurring through increased transcription rates, or 
stabilisation of the AR mRNA or protein (Dehm and Tindall, 2005; Edwards et 
al, 2003). Interestingly, studies have shown that patients with AR 
amplification had an increased likelihood of responding to second-line 
hormone therapies compared with patients without AR gene amplified 
tumours, possibly due to the fact that these tumours were more differentiated, 
allowing the patients to have a better outcome (Koivisto et al, 1997; Palmberg 
et al, 2000). Amplifications of the AR gene highlight the strong selective 
pressure for continued AR signalling as tumours evolve in an environment of 
androgen deprivation, and provide impetus for development of more 
effective AR signal inhibition.
Certain growth factors, such as IGF-1, KGF and epidermal growth 
factor (EGF) can activate the AR, creating an /z outlaw receptor" which has the 
potential to induce AR target genes in the absence of androgen (Culig et al, 
1994). These growth factors can initiate complex intracellular signalling 
cascades by activating the high-affinity, cell surface receptor tyrosine kinase. 
IGF-1, the most potent of the factors tested, has been shown to induce a 
fivefold rise in PSA secretion in LNCaP cells (Culig et al, 1994). Significantly, 
increased circulating levels of IGF have been correlated with prostate cancer 
risk (Chan et al, 1998). On the other hand, the AR antagonist bicalutamide 
completely blocks activation of the AR by IGF-1, KGF and EGF (Culig et al,
1994) indicating that the AR LBD is necessary for this activation.
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In addition, cellular expression of the EGF receptor family member 
human epidermal growth factor receptor 2 (HER-2) increases during prostate 
cancer progression (Signoretti et al, 2000) and can activate AR-dependent 
genes in the absence of AR ligand. However, unlike the effect of IGF-1, AR 
activity created by HER-2 overexpression could not be blocked by 
bicalutamide, indicating that this pathway is independent of the AR LDB 
(Craft et al, 1999). Further study of AR activation through HER-2 suggests that 
both the mitogen-activated protein kinase (MAPK) and the protein kinase Akt 
signalling pathways play important roles in mediating this effect. In cell lines, 
MAPK-mediated AR activation can stimulate growth by phosphorylating the 
AR, leading to AR activation (Yeh et al, 1999). Akt that has been activated by 
HER-2 signalling also phosphorylates the AR turning it into an androgen- 
independent receptor, which can promote both the growth and survival of 
prostate cancer cells cultured in steroid-depleted media (Wen et al, 2000). 
Furthermore, PTEN, a lipid phosphatase that negatively regulates the Akt 
pathway, allowing cells to undergo apoptosis, is functionally inactivated in 
upwards of 80% of prostate cancers. This leads to increased activation of Akt 
and subsequent activation of a downstream protein important for cell growth, 
mTOR (Scher and Sawyers, 2005). Furthermore, increased 
phosphatidylinositol (3,4,5)-trisphosphate (PIP3) levels, generated either by 
phosphatidylinositol 3-kinase (PI3K) activation or by PTEN loss, activate 
downstream kinase pathways including Akt, which enhance AR 
phosphorylation, resulting in a receptor that is more stable and with increased 
transactivation activity (Scher and Sawyers, 2005).
IL-6, a cytokine that plays a central role in host defence due to its wide 
range of immune and hematopoietic activities and also influences the growth 
of normal and cancer cells, has been shown to be significantly elevated in
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patients with CRPC (Drachenberg et al, 1999). It has been shown to increase 
proliferation of prostate cancer cells by binding to its receptor and activating 
signal transducers and activators of transcription (STATS) as well as MAPK in 
LNCaP cells. IL-6 increases MAPK phosphorylation and activates the AR 
NTD. Furthermore, direct interaction between the AR NTD and STATS in IL- 
6-treated LNCaP cells has also been shown, suggesting that IL-6 is involved in 
the androgen-independent progression of prostate cancer (Suzuki et al, 2003).
The transcriptional activity of the AR is mediated through a large 
number of interacting proteins that function as coactivators or corepressors. 
The expression and activity of AR-associated coregulatory partners has been 
directly implicated in mediating AR sensitivity to low concentrations of 
androgens as well as stimulating the receptor in response to alternative 
ligands (Dehm and Tindall, 2005). The best characterised of these coactivators 
are the steroid receptor coactivator (SRC) proteins SRC-1, SRC-2 and SRC-3. 
When combined with AR's that have LBD mutations, SRC-1 up-regulates the 
transcriptional activity of AR in a ligand-dependent manner, a process 
regulated through phosphorylation by MAPK (Suzuki et al, 2003). On the 
other hand, increased levels of expression of SRC-1 and SRC-2 have been 
found in clinical samples from androgen-independent prostate cancer. 
Further studies indicate that SRC-1 can augment AR transcriptional activity in 
the presence of bicalutamide, indicating that increased coactivator expression 
could be a mechanism contributing to AR activity in androgen-independent 
prostate cancer. The best characterised corepressors are the nuclear receptor 
corepressor (NCoR) and silencing mediator for retinoid and thyroid (SMRT) 
hormone receptors. These bind to unliganded nuclear receptors and repress 
transcription through recruitment of HDACs. Corepressor complexes 
containing HDAC enzymes maintain chromatin in a configuration that
25
Introduction
excludes functional interactions of the general transcriptional machinery with 
the promoter (Yu et al, 2001).
Resistance to ADT can also arise via pathways that bypass AR and 
protect cells from castration-induced apoptosis through androgen- 
independent upregulation of antiapoptotic molecules, such as Bcl-2 (Setlur 
and Rubin, 2005). Bcl-2 is not normally expressed in the secretory epithelial 
cells of the prostate, however, Bcl-2 is frequently expressed in PIN as well as 
in CRPC (Cleave et al, 1999). Furthermore, Bcl-2 expression was detected in 
tumours that initially did not express it, but emerged after selecting for 
growth of prostate cancer xenografts in castrated mice (Liu et al, 1996). Hence, 
it has been hypothesised that the up-regulation of such anti-apoptotic 
proteins could bypass the signal for apoptosis that is normally generated by 
androgen ablation, and allow for the survival of cells.
Finally, in contrast to the proposed model of tumourigenesis, in which 
every cell within the tumour is potentially tumour-initiating, the stem cell 
model of cancer postulates that only a rare subset of cells are tumourigenic 
(Colombel et al, 1993). This zTurker cell pathway" has been proposed to arise 
from pre-existing AR-negative stem cells that are resistant to castration and 
might continuously repopulate the prostate. Although these cells remain a 
small percentage of the actual percentage of the tumour, they are not affected 
by ADT and can differentiate into androgen-dependent and independent 
cells, resulting in the heterogeneous AR phenotype that is observed in CRPC 
patients (Shah et al, 2004).
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1.5 New generation of androgen deprivation therapy for prostate 
cancer
Studies have shown that an incomplete response to ADT and subsequent 
disease progression occurs as a result of continued AR signalling. As a result, 
several new and more effective therapies that target the androgen axis have 
been designed to address this potential mechanism of resistance.
Abiraterone acetate (Cougar Biotechnology), is a specific inhibitor of 
CYP17A1, a rate-limiting enzyme in androgen biosynthesis. As a result of the 
inhibition of its enzymatic activity at two sequential steps in the androgen 
biosynthesis pathway, reduced levels of dehydroepiandrosterone and 
androstenedione synthesis limit the subsequent conversion to testosterone 
and DHT (Harris et al, 2009). Given its key role in androgen production, 
inhibition of CYP17A1 would be expected to suppress androgen production 
in all endocrine organs, including the testis and adrenal glands (Reid et al, 
2008). Abiraterone was approved by the U.S. Food and Drug Administration 
(FDA) as a second line chemotherapy in April 2011 (Osanto and Van Poppel, 
2012) after showing an increase in overall survival of 4 months and is 
currently in a Phase III trial to determine its effects in chemotherapy-naive 
CRPC patients (Osanto and Van Poppel, 2012).
Along the lines of abiraterone acetate, TAK-700 (Millennium 
Pharmaceuticals), a CYP17 inhibitor with greater 17,20 lyase selectivity, may 
improve the safety profile as compared with agents that inhibit both steps in 
the testosterone synthesis process (Agarwal et al, 2011; Massard and Fizazi, 
2011). TAK-700 is currently being tested in both the pre- and post-docetaxel 
settings in two randomised Phase III trials carried out in men w ith CRPC 
(Massard and Fizazi, 2011).
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MDV-3100 (Medivation, Inc.) is a small molecule AR antagonist that 
binds AR in cells with 10-fold higher affinity that bicalutamide and impairs 
AR nuclear translocation and blocks DNA binding (Mellado et al, 2009). The 
drug was identified as a result of its activity in AR overexpression models, in 
which conventional antiandrogens developed agonistic properties. Two 
placebo-controlled Phase III trials evaluating MDV3100 in the pre and post 
chemotherapy setting were initiated: The AFFIRM trial showed that in 
patients who had previously received chemotherapy MDV3100 prolonged 
survival by 5 months. The PREVAIL trial is currently undergoing in 
chemotherapy-naive patients and a Phase II trial is also ongoing in hormone- 
naïve men, i.e. patients who have not received prior hormone therapy.
In addition, a small molecule has been identified by Marianne Sadar 
that blocks transactivation of the amino-terminal domain of AR. This 
experimental compound, EPI-001, isolated from a screen of marine sponge 
extracts, was specific for inhibition of AR without attenuating transcriptional 
activities of related steroid receptors (Andersen et al, 2010). EPI-001 interacts 
with the AF1 transcription activation site, inhibiting protein-protein 
interaction with the AR, and reducing AR interaction with androgen-response 
elements on target genes (Andersen et al, 2010). The efficacy of EPI-001 
relative to other currently-proven therapeutic agents is being tested in CRPC 
models by ESSA Pharma Inc (Vancouver, BC).
1.6 Novel androgen receptor splice variants
Although androgens are depleted in CRPC, AR-mediated functions are not 
completely abrogated and prostate métastasés still express nuclear AR and 
androgen regulated genes. Therefore, CRPC continues to depend on AR-
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mediated functions but bypasses the requirement for physiologic levels of 
androgens (Scher and Sawyers, 2005). Despite the established clinical 
relevance of these well-characterised AR alterations in CRPC, a few recent 
studies have suggested an alternative mechanism for CRPC and investigated 
the putative role of AR variants lacking the AR LBD (Céraline et al, 2004; 
Libertini et al, 2007). The first in vitro studies carried out to describe AR 
variants showed that AR deletion mutants, with the entire carboxy-terminal 
LBD deleted, were constitutively active in the absence of androgens (Jenster et 
al, 1991; Simental et al, 1991) indicating that the LBD, in addition to being 
responsible for binding to androgen, might also serve as a negative regulator 
of AR transcriptional activity. However, at the time of their discovery, it was 
unclear whether such constitutively active AR isoforms were naturally 
expressed in human tissues and if so, what were their functions.
For more than a decade, researchers observed that, in addition to the 
canonical 100 kDa AR protein, other lower molecular weight protein bands 
were also detected by an antibody specific to the N-terminal region of AR in 
certain AR-positive cell lines (Guo and Qiu, 2011). However, the explanation 
for the origins of these AR short form variants was not clear and at least four 
potential mechanisms underlying generation of short form AR proteins were 
proposed: (i) alternative translation start codons; (ii) proteolytic cleavage; (iii) 
premature stop codon resulting from mutations; and (iv) alternative 
transcription start sites (Guo and Qiu, 2011).
Key observations leading to their discovery were initially reported in 
2001, when Tepper and colleagues identified a mutant AR in the prostate 
cancer cell line 22Rvl, known to contain a tandem duplication of exon 3 
encoding the second zinc finger of the DBD, which appeared to have rendered 
AR susceptible to protease cleavage, generating a constitutively active form
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around 80 kDa (Tepper et al, 2002) referred to as ARALBD because it lacked 
the ligand binding domain. Additional biochemical characterisation revealed 
that this ARALBD isoform was constitutively nuclear and able to bind DNA 
independently of androgens. Further co-immunoprecipitation experiments 
showed that the ARALBD isoform did not interact with full-length AR, 
suggesting that this truncated version of AR functioned as an independent 
factor. In another study, looking at benign and cancerous prostate tissue 
showed that protein levels of this ARALBD isoform were expressed at a 
higher level in clinical prostate cancer (Libertini et al, 2007). However, several 
recent studies have suggested that alternative splicing could also be an 
important contributor to the synthesis of truncated AR species lacking the AR 
LDB in these and other cells based on observations of differential siRNA 
targeting of the various AR species in 22Rvl cells (Dehm et al, 2008). 
Functionally, androgen-dependent expression of AR target genes and 
androgen-dependent cell growth was shown to be attributable to full-length 
AR, whereas androgen-independent expression of AR target genes and 
androgen-independent growth was shown to be supported by the different 
truncated AR protein species observed in these cells, providing the 
foundation for many groups to clone and identify multiple alternatively 
spliced AR variants by 3'-RACE and other approaches (Figure 1.6) (Dehm et 
al, 2008; Guo et al, 2009; Hu et al, 2009, 2011; Marcias et al, 2010; Sun et al, 
2010).
The clinical significance of these variants is currently a focus of many 
research groups. Several studies report that the elevated expression of the AR 
splice variant AR-V7 (or AR3), one of the most extensively characterised AR 
variants, was found to be associated with more rapid disease recurrence 
following radical prostatectomy for localised disease, when compared w ith
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Figure 1.6 Alternatively spliced AR isoforms identified in prostate cancer. The hatched 
cassettes indicate cryptic exons and solid thick lines represent the transcribed exon sequences 
(Guo and Qiu, 2011).
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patients with lower expression of the variant (Guo et al, 2009; Hu et al, 2009). 
Interestingly, the splice forms were not expressed in the nucleus of normal 
prostate epithelium and rarely at considerable levels in primary prostate 
cancer (Figure 1.7). These data suggest that the presence of constitutively 
active splice variants of the AR arises following castration and plays a role in 
the progression of prostate cancer.
Another novel AR mRNA isoform arising through skipping of exons 5, 
6 and 7, termed ARv567, was identified in a panel of 25 different prostate 
cancer xenografts, termed the LuCaP series, most of which derived from 
métastasés obtained from men with CRPC after prolonged expose to 
androgen-deprivation therapy (Sun et al, 2010). Due to the alternative splicing 
of exon 4 to the start of exon 8, a frame shift occurs that generates a new stop 
codon after the first 29 nucleotides of exon 8 (Sun et al, 2010). Thus, this makes 
the ARv567 protein smaller than the wild-type AR, but also, gives it a unique 
10-amino acid termination sequence. The authors determined that ARv567 is 
constitutively active and that it also increases expression of the full-length AR 
and enhanced transcriptional activity of AR in the absence of the ligand (Sun 
et al, 2010). This variant, unlike the previously reported AR splice variants, 
retains the hinge region, known to be necessary for complete nuclear 
translocation of the AR, and genomic DNA sequencing of each AR exon and 
intron flanking regions suggest that the ARv567 is a result of alternative 
mRNA splicing (Sun et al, 2010). Moreover, ARv567 was also shown to 
interact with full-length AR and enhance its ligand-dependent and ligand- 
independent activity, perhaps through a mechanism of protein stabilisation or 
even induction of full-length AR translocation to the nucleus in the absence of 
androgens (Dehm and Tindall, 2011).
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Figure 1.7 Immunohistochemistry analysis on human prostate tissue sections using an AR- 
V7 specific antibody. In the left panel, AR-V7 expression is virtually undetected in luminal 
epithelial cells. In the centre panel, AR-V7 is detected in luminal epithelial cells in adjacent 
prostatic intraepithélial neoplasia (PIN). In the right panel, nuclear staining of AR-V7 is 
enhanced in hormone-resistant (HR) tumours (Guo and Qiu, 2011).
Even though canonical full-length AR and AR variants are both 
increased in CRPC, their expression regulation and functional relationships 
had not been fully dissected. Studies on the transcriptional programs induced 
by variant signalling have shown that an adaptive shift toward AR-variant- 
mediated signalling occurs in a subset of CRPC tumours, suggesting an 
important mechanism contributing to drug resistance to CRPC therapy (Hu et 
al, 2012). Specifically, increased expression of both AR-V7 and ARv576 has 
been shown to correlate with the expression of cell cycle genes, which were 
induced under both androgen-depleted and androgen-stimulated conditions. 
On the other hand, genes related to metabolism, biosynthesis and secretion 
dominated the top gene sets found to be increased by ligand-dependent full- 
length AR (Hu et al, 2012). Furthermore, AR variants do not rely on full-length 
AR for their transcriptional activity since the absence of full-length AR did not 
attenuate the variant signature. Moreover, treatments targeting the AR LBD 
such as MDV3100 and abiraterone were found to increase AR-V7 and ARv567 
expression in CRPC xenografts as well as in prostate cancer cell lines (Hu et al, 
2012). Therefore, the therapeutic efficacy of these agents may be compromised 
as a consequence of this adaptive shift.
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1.7 Microtubules as chemotherapy targets
1.7.1 Microtubule functions in cell biology
The cell cytoskeleton is comprised of three families of protein filaments, 
which are fundamental to the spatial organisation of cells: actin filaments, 
intermediate filaments and microtubules. Microtubules play important roles 
in a plethora of cellular processes that range from cell signalling and 
trafficking to cell division and structural support. They are long, hollow, 
cylindrical protein polymers composed of a /  p-tubulin heterodimers. The 
tubulin heterodimers assemble in a head-to-tail fashion to form 12-13 
protofilaments. The protofilaments associate longitudinally to form a sheet, 
which then closes up to form a microtubule with a diameter of 25 nm (Figure
1.8) (Amos and Klug, 1974).
The functional diversity of microtubules is achieved in specific ways: 
through the binding of various regulatory proteins, including microtubule 
associated proteins (MAPs), by expression of different tubulin isotypes and 
through post-translational modifications of tubulin (Jordan and Wilson, 2004). 
Microtubules are extremely important in the process of mitosis and their 
dynamics are the target of a chemically diverse group of antimitotic drugs. 
The biological functions of microtubules in all cells are determined and 
regulated in large part by their polymerisation dynamics, i.e. their ability to 
rapidly polymerise and depolymerise. These rapid changes in growth and 
shrinkage allow microtubules to adopt specific arrangements w ithin the cell 
that can rapidly change in response to cellular demands (Desai and 
Mitchison, 1997). During cell division for instance, microtubule dynamics 
increase significantly (4-100 fold) to enable fast "Search-and-Capture" 
functions required for mitosis (Jordan et al, 2002).
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Figure 1.8 The structure of the microtubule polymer. a/|3-tubulin heterodimers polymerise 
to form microtubules, long cylinders consisting of 13 linear protofilaments assembled around 
a hollow 24 nm diameter core. The head-to-tail arrangement of tubulin dimers results in polar 
structures with two distinct ends. The fast-growing microtubule plus end has an exposed (3- 
tubulin subunit and the slow-growing minus end has an exposed a-tubulin subunit (Jordan 
and Wilson, 2004).
Microtubules utilise the energy of adenosine-5z-triphosphate (ATP) 
hydrolysis to fuel a unique polymerisation mechanism termed dynamic 
instability with alternating phases of growth and shrinkage (Jordan and 
Wilson, 2004). Dynamic instability, first described by Tim Mitchison and Marc 
Kirschner in 1984 (Mitchison and Kirschner, 1984), is critical for cytoskeletal 
remodelling, and results in the continual turnover of microtubules due to 
nucleotide hydrolysis. Polymerisation is achieved by the addition of free a/(3- 
tubulin dimers at one end of the microtubule, called the "plus-end" due to its 
increased dynamicity. The other less dynamic end of the microtubule polymer 
is called the /zminus-endz/. The tandem polymerisation of a /p-tubulin  
heterodimers results in an inherent heterogeneity between the two ends of the 
microtubule; a-tubulin is exposed at the less dynamic end, and p-tubulin is 
exposed at the more dynamic end (Zhou and Giannakakou, 2005) (Figure 1.9). 
The minus ends are associated with the microtubule organising centre
35
Introduction
(MTOC) and are located in the centre of the cell near the nucleus, while the 
plus ends are distributed around the cell periphery. At steady-state the rate of 
addition of free-tubulin dimers at the plus-end of a microtubule equals the 
rate of removal of tubulin subunit from the minus-end, resulting in 
preservation of the length of a microtubule, while it continues being dynamic 
and exchanging subunits between the cellular pools of polymerised and 
soluble tubulin (Jordan and Wilson, 2004).
Stable or capped microtubule Tubulin-bound GDP Tubulin-bound GTP
8 ^ 8Tubulin-bound GTP or GDP-Pi
Cap los
Depoly merizing 
microtubule
Tubulin-bound GDPmmmm
% 8
Figure 1.9 Regulation of dynamic instability. A microtubule end containing GTP-bound 
tubulin is stable, or "capped", against depolymerisation. GTP hydrolysis results in a 
conformational change in the tubulin molecules that destabilises the microtubule polymer, 
resulting in catastrophe and shortening of the microtubule (Jordan and Wilson, 2004).
GTP hydrolysis strongly influences the strength of lateral interactions 
between protofilaments. This interaction is stronger in the GTP-bound state 
than in the GDP-bound state; the lateral interaction is strong enough with 
GTP bound to favour polymerisation through lateral aggregation of 
protofilaments, while with GDP bound the weaker lateral interactions allow 
protofilaments to separate from each other, and the microtubules rapidly
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dissociate (Downing and Nogales, 1999). These lateral interactions must be 
regulated in order to produce a balanced level of dynamic instability. Any 
changes in microtubule stability that are not under the celTs control are likely 
to interrupt or inhibit critical events in the cell cycle.
1.8 Microtubule-based transport
The inherent polarity of microtubules is essential for the directional flow of 
information within the cell. This polarity is utilised by microtubule-associated 
motor proteins, kinesins and dyneins that move cargoes towards the cell's 
periphery or the cell's nucleus, respectively (Figure 1.10).
Three large superfamilies of molecular motors have been identified 
that are involved in intracellular transport -  kinesins, dyneins and myosins 
(Hirokawa and Takemura, 2005; Vale, 2003). Myosins move along actin 
filaments, whereas kinesins and dyneins move along microtubules (Kardon 
and Vale, 2009). The kinesin-related proteins transport cargoes towards the 
plus end of microtubules using the chemical energy of ATP and have specific 
roles in mitotic and meiotic spindle formation and chromosome separation 
during cell division as well as in plasma membrane targeting (Hirokawa et al, 
2009). The dyneins are "minus-end-directed" motor proteins that couple ATP 
hydrolysis to movement along microtubules. There are two types of dynein 
motors: axonemal and cytoplasmic. Axonemal dyneins are responsible for the 
beating of cilia and flagella, while cytoplasmic dyneins carry a large variety of 
cargoes (membranous organelles, protein complexes and mRNAs) as well as 
driving the movement of the ER-Golgi complexes near the cell centre (Carter 
and Vale, 2010).
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Figure 1.10 Microtubule polarity in motor protein transport. Plus-end directed motor 
proteins, kinesins, are responsible for the movement of cargo on microtubules towards the 
cell membrane, whereas minus-end directed motor proteins, the dyneins are responsible for 
the movement of cargo on microtubules towards the nucleus (Komlodi-Pasztor et al, 2011).
There are thought to be around 45 kinesin genes in mammals but only 
one type of cytoplasmic dynein (Hirokawa et al, 2009) as each member of the 
kinesin family transports a specific cargo thought to be related to their unique 
tail domain. Whereas dynein is more complex and requires a large complex of 
associated proteins that link the cargoes to the motor but do not exert any 
movement by themselves.
Dyneins are the largest of the known molecular motors as well as being 
amongst the fastest. They are composed of a heavy chain, an ATPase, which 
powers motility along microtubules and several non-catalytic subunits, which 
provide points of attachment for dynein cargoes. The heavy chain consists of 
a carboxy-terminal motor (head) domain and an amino-terminal tail domain. 
The motor domain contains six AAA domains (ATPases associated with a 
variety of cellular activities) arranged in a ring and a microtubule-binding 
domain at the end of a 10 nm long anti-parallel coiled-coil stalk that extends 
out from the AAA ring (Roberts et al, 2009). The amino-terminal tail of the
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heavy chain is involved in its homodimerisation and acts as a scaffold for the 
assembly of five different non-catalytic subunits (Figure 1.11).
Figure 1.11 Structure of cytoplasmic dynein. The dynein heavy chain is composed of a 
carboxy-terminal motor domain (head) and an amino-terminal tail domain. The motor head 
hydrolyses ATP and uses the chemical energy to drive conformational changes that generate 
motile force. The dynein intermediate chain (IC) and light intermediate chain (LIC) bind 
directly to the dynein heavy chain. The smaller light chains (LC7 and LC8) and the T-complex 
testis-specific protein 1 (TCTEX1) assemble on the IC and mediate interactions with several 
dynein adaptor proteins (shown in blue boxes), such as dynactin (Kardon and Vale, 2009).
Dynein interacts with accessory proteins that do not belong to the 
dynein complex itself but are crucial for adapting the motor to its cellular 
function (Kardon and Vale, 2009). The best characterised is dynactin, which is 
required to translocate organelles effectively. Dynactin helps to target dynein 
to specific cellular locations, links dynein to cargoes and increases dynein 
processivity (Kardon and Vale, 2009), however, how dynactin carries out 
these functions remains unknown. Microtubules and their associated motors
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are known to play a crucial role in the transport of vesicles and organelles. In 
addition to transporting membrane vesicles in the endocytic and secretory 
pathways, microtubule-based motor proteins are also involved in positioning 
membrane-enclosed organelles, such as the endoplasmic reticulum, Golgi 
apparatus, lysosomes, and mitochondria within the cell (Hirokawa, 1998). In 
addition, dynein is also critically involved in the intracellular trafficking of 
protein complexes, viruses (Leopold and Pfister, 2006), tumour suppressor 
proteins such as p53 (Giannakakou et al, 2000) and the retinoblastoma protein 
(Rb) (Roth et al, 2007), and nuclear receptors such as the parathyroid hormone 
(PTH)-receptor protein (PTHrP) (Lam et al, 2002) and the glucocorticoid 
receptor (GR) (Harrell et at, 2004). Therefore, the role of dynein in the nuclear 
transport of the AR will be elucidated in this study.
1.9 Taxanes in clinical oncology
Taxanes represent some of the most widely used cancer chemotherapeutic 
agents in clinical oncology. Generally originating from natural sources, the 
identification of the chemically diverse compounds known as microtubule- 
targeting drugs began over 50 years ago, when the vinca alkaloids were first 
found to alter microtubule function (Noble et al, 1958). This breakthrough was 
later followed by the isolation of the pioneering taxane, paclitaxel (Taxol) 
from the bark of the Pacific yew tree Taxus brevifolia in the 1960s (Ward et al, 
1971; Schiff et al, 1979). Since its FDA approval in 1992, paclitaxel has been 
used in a wide range of malignancies such as ovarian, breast, lung, prostate 
and head and neck cancers. In addition, a more potent taxane, docetaxel 
(Taxotere), a semisynthetic analogue of paclitaxel, was first approved by the 
FDA in 2004 for advanced breast cancer and is since used in the treatments of 
CRPC, non-small cell lung cancer (NSCLC) and gastric cancer. Taxanes act by
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binding to microtubules at the taxane binding site located on the inner surface 
of the microtubule. They promote the assembly of tubulin into microtubules 
and simultaneously inhibit disassembly, thereby stabilising microtubule 
dynamics (Jordan and Wilson, 2004). Suppression of microtubule dynamics, 
required for cell division and vital interphase processes, results in the 
blockade at the metaphase-to-anaphase transition of mitosis by preventing the 
normal formation of mitotic spindles, leading to cell death (Gascoigne et al, 
2009). During mitosis, interphase microtubules rapidly depolymerise and are 
substituted by microtubules 4 to 100 times more dynamic that form the 
bipolar mitotic spindle, essential for the correct segregation of sister 
chromatids during mitosis (Jordan et al, 2002). In prophase, the centrosomes 
move apart to form the spindle poles and the chromosomes condense. In 
prometaphase, the microtubules elongate from each spindle pole and upon 
entry into metaphase the duplicated chromosomes attach to the microtubules 
at their kinetochore (McGrogan et al, 2008). At this point the spindle assembly 
checkpoint (SAC) is activated to ensure correctly connected kinetochores to 
spindle microtubules and prevents the onset to anaphase until all 
chromosomes have been properly aligned at the metaphase plate (Musacchio 
and Salmon, 2007). The SAC is silenced when correct bi-orientation of the 
sister chromatids has occurred after they oscillate back and forth in order to 
create the appropriate tension, generating a signal which causes them to 
separate and enter anaphase (Weaver and Cleveland, 2005). This tension is, in 
part, produced by dynamic microtubules, which during metaphase are 
continuously adding tubulin to the plus end (the kinetochore) and loosing 
tubulin at the minus end (the spindle poles) (Jordan et al, 2007). If this tension 
is lost the cell cycle cannot progress and is blocked at anaphase. Taxane 
treatment of cells stabilises microtubules and although chromosomes are able 
to attach to taxane-stabilised microtubules, the lack of microtubule dynamics
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diminishes the tension produced between the duplicated chromosomes 
preventing correct chromosome bi-orientation (Kelling et al, 2003), leading to 
activation of SAC, which in turn leads to mitotic arrest.
To reach its binding site on the lumen of the microtubule, paclitaxel is 
thought to diffuse through nanopores in the microtubule polymer, a process 
mediated by the formation of a hydrogen bond between paclitaxel and serine 
275 in p-tubulin (Freedman et al, 2009). In electron crystallographic models 
(Nogales et al, 1998; Nogales et al, 1999), the binding pocket for paclitaxel 
resides in a deep hydrophobic cleft near the surface of p-tubulin, facing the 
inside of the microtubule where it interacts with the protein by means of three 
hydrogen bonds and multiple hydrophobic contacts (Snyder et al, 2001). 
Further identification of interactions between microtubules and paclitaxel has 
shown that the main interaction between adjacent protofilaments appears to 
involve the M loops of one protofilament with the H3 helices from the other 
(Figure 1.12). This suggests that the main effect of paclitaxel is to stabilise the 
conformation of the M loop and thus stabilise lateral interactions locking the 
microtubule in a straight conformation and counteracting the conformational 
change in helix H3 that follows hydrolysis (Downing and Nogales, 1999).
There is one taxane-binding site on every molecule of tubulin in a 
microtubule and the ability of taxanes to increase microtubule polymerisation 
is associated with nearly 1:1 stoichiometric binding of taxanes to tubulin. 
Taxane binding does not prevent the binding of other microtubule-targeting 
agents such as colchicine or vinblastine to tubulin (Figure 1.12) (Kumar, 1981) 
and reduces the number of protofilaments from 13 to 12 (Diaz et al, 1998). 
Paclitaxel binds very poorly to soluble tubulin, but has very high affinity for 
the microtubule polymer (Nogales et al, 1995) with an apparent binding 
constant, Kapp, of 8.7 x lO 7 M (Parness and Horwitz, 1981). In vivo, paclitaxel
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Figure 1.12. Microtubule-targeting drugs bind tubulin at different sites. On the left panel, 
ribbon diagram of the tubulin dimer shows paclitaxel bound to the (3 subunit in the interior 
lumen of the microtubule. On the right panel, a close up of the paclitaxel-|3-tubulin complex 
illustrating the important binding interactions (Snyder et al, 2001).
increases the mass of the microtubule polymer at physiologically relevant 
doses (-100 nM in plasma), as well as inducing microtubule bundle formation 
in interphase cells. Microtubule bundling has become a hallmark of taxane 
binding and is now recognised as a characteristic of microtubule stabilisation 
(Schiff and Horwitz, 1980). However, the formation of microtubule bundles 
occurs only above a threshold concentration of drug. At concentrations less 
than 10 nM, paclitaxel potently suppresses microtubule dynamics, without 
affecting polymer mass (Jordan et al, 1993). Docetaxel, a more water-soluble 
analogue of paclitaxel, binds to the same site on microtubules as paclitaxel, 
but with double the affinity and therefore, is slightly more potent in its effects 
on cells and on tubulin polymerisation (Diaz and Andreu, 1993).
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1.10 Taxane resistance
Despite the effectiveness of the taxanes, their ability to cure cancer is limited 
by acquired drug resistance (Cabral, 2008). Drug resistance is the most 
common reason for the failure of drug treatment in cancer patients who 
initially respond to chemotherapy but eventually relapse and their tumours 
become refractory to further treatment (Giannakakou and Snyder, 2008).
Several mechanisms of resistance have been described for paclitaxel. 
There are mechanisms that involve alterations in the a- and p-tubulin 
subunits such as differential expression levels of p-tubulin isotypes, increase 
in microtubule dynamics, decreased ability of paclitaxel to suppress 
microtubule dynamics in cells over-expressing the pill-tubulin isotype and 
the presence of tubulin mutations that impair the drug's ability to interact 
with tubulin (Giannakakou and Snyder, 2008). Another possible mechanism 
of resistance is the presence of mutations in the drug binding site on the p~ 
tubulin subunit of microtubules. However, at present, clinical research on p~ 
tubulin mediated paclitaxel resistance has been addressed only in one study 
(Monzô et al, 1999). Thus, in 1999, Monzô and colleagues demonstrated a 
clear-cut clinical correlation between the occurrence of mutations at p-tubulin 
exon 4 and resistance to paclitaxel in NSCLC patients. The results of the study 
were categorical; no clinical response in 16 patients for whom p-tubulin 
nucleotide sequencing alterations were noted. In addition, these alterations 
were shown to be a negative prognostic marker for survival. However, this 
study has been the centre of scientific controversy and highly criticised since 
different research groups were unable to confirm the tumour-specific 
mutations in the p-tubulin gene and suggest that Monzô and colleagues' 
findings resulted from interferences derived from tubulin pseudogenes (p- 
tubulin-like peptides) during the sequencing of the gene (Kelley et al, 2001;
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Tsurutani et al, 2002; Kohonen-Corish et al, 2002). Furthermore, acquired 
resistance to paclitaxel by specific point mutations in tubulin were reported in 
two paclitaxel-resistant human ovarian carcinoma cell lines (Giannakakou et 
al, 1997), being the first study to report alterations involving tubulin that 
result in paclitaxel resistance in human cells. However, clinical confirmation 
of this correlation has been difficult to obtain due to the lack of relevant 
biopsies from metastatic sites and the poor sensitivity of the sequencing 
assays used. An important limitation of the taxanes is that they have high 
substrate affinity for multidrug-resistance proteins, in particular the ATP- 
dependent drug efflux pump P-glycoprotein (P-gp), for which it has an 
affinity Kd of 37 nM (Sharom et al, 2001). Expression of P-gp by cancer cells 
can be responsible for both constitutive and acquired resistance to taxanes 
(Jordan and Wilson, 2004). However, no correlation has been found between 
P-gp expression and sensitivity to taxanes in the clinical setting. Furthermore, 
the only FDA approved P-gp inhibitor, the calcium channel inhibitor 
verapamil, is used as an anti-arrhythmic agent. It was found to have limited 
success in conjunction with chemotherapy due to the cardiac toxicity 
associated with the high plasma levels required to reverse the multidrug 
phenotype (Martin et al, 1999). Additional resistance to taxanes may be 
conferred by mutations in other less-well characterised transporters. 
Moreover, the increased expression of antiapoptotic proteins such as Bcl-2 
may also confer a relative degree of resistance to the taxanes in addition to 
post-translational modifications that modify regulatory protein binding 
(Takimoto and Beeram, 2008).
Limited treatment options for men with metastatic CRPC expanded in 
2004 when the combination of docetaxel and prednisone was established as 
the new standard of care for patients who have progressed on androgen
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deprivation based on two prospective randomised trials showing a 
prolongation of life relative to mitoxantrone and prednisone, the previous 
standard (Tannock et al, 2004; Petrylak et al, 2004). The trials showed that 
patients receiving docetaxel together with estramustine had a 20% reduction 
in the risk of death compared to those patients with mitoxantrone and 
prednisone and an improvement in median survival of nearly two months 
(Petrylak et al, 2004). The clinical studies also showed that administration of 
docetaxel decreases serum PSA levels by at least 50% in patients with CRPC 
(Tannock et al, 2004; Petrylak et al, 2004). Subsequent reports have shown that 
docetaxel down-regulates the expression of androgen receptor and PSA in 
prostate cancer cell lines, suggesting that docetaxel-induced down-regulation 
of AR might be one of the anti-tumour mechanisms active in prostate cancer 
(Kuroda et al, 2009). However, taxane chemotherapy has a favourable 
palliative response in 50-70% of men with CRPC; nevertheless most will die 
within 1-2 years (Savarese et al, 2001).
An added line of therapy for patients with CRPC came in June 2010, 
when the new taxane, cabazitaxel, in combination with prednisone, was 
approved by the FDA for treatment of patients who have previously been 
treated with a docetaxel-based regimen. The randomized trial showed that 
patients receiving cabazitaxel had statistically significantly longer overall 
survival compared with those receiving mitoxantrone (de Bono et al, 2010). 
The median survival time of patients in the cabazitaxel group was 15.1 
months compared with 12.7 months for patients in the mitoxantrone group 
(de Bono et al, 2010). Therefore, it is clear that taxanes have an effect on CRPC, 
suggesting that microtubules have unknown functions on prostate cancer cell 
survival.
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1.11 Hypothesis
Traditionally the taxanes were thought of as anti-mitotic drugs, an idea that 
stems from their targeting of rapidly diving cells in tissue culture (Jordan and 
Kamath, 2007). However, patients' tumours have significantly slower rates of 
cell division than cancer cells growing in vitro. For example, prostate cancer 
doubles every 33 to 577 days (Berges et al, 1995; Komlodi-Pasztor et al, 2011), 
in contrast to the rapidly dividing prostate cancer cells grown in tissue culture 
with doubling times between 30 to 48 hours (Ghosh et al, 2006; Butterworth et 
al, 2008). Therefore, mitotic arrest cannot alone account for the therapeutic 
benefit of taxane-based chemotherapy (Komlodi-Pasztor et al, 2012; Gascoigne 
and Taylor, 2008). Thus, the effects of taxanes on interphase microtubules and 
the cellular pathways that depend directly on intact microtubules provides an 
alternate mechanism of action for this class of drugs. Although this notion 
challenges the existing paradigm of taxanes exerting their clinical activity 
exclusively through inhibition of mitosis, by shifting the focus to interphase 
microtubules, it provides a unique opportunity to dissect how these drugs 
work and why they are not effective in all tumour types and all patients. 
Moreover, previous studies that have implicated a microtubule-facilitated 
nuclear import pathway for p53 (Giannakakou et al, 2000), Rb (Roth et al, 
2007) and the PTHrP (Lam et al, 2002), suggest that certain cancer regulatory 
proteins utilise a microtubule-enhanced pathway for accelerated nuclear 
import that is required for their nuclear functions.
With this in mind, the goal of the present study is to investigate the 
molecular basis underlying the taxane-mediated inhibition of AR signalling in 
preclinical models of prostate cancer. While taxanes are thought to exert their 
anti-tumour effect by inducing mitotic arrest of actively dividing cells, it was 
hypothesised that taxane targeting of interphase microtubules will also affect
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biological processes critical for prostate cancer survival and progression. 
Given the critical role of AR in disease progression of CRPC and the clinical 
efficacy of taxanes in this disease, it was hypothesised that AR associates with 
the microtubule cytoskeleton in order to traffic towards the nucleus following 
ligand binding. Therefore, the clinical activity of taxanes in prostate cancer 
patients is mediated in part by inhibition of AR nuclear accumulation and 
activity which occurs downstream of taxane-induced microtubule- 
stabilisation.
To investigate this hypothesis the following aims will be investigated:
I. Investigate the molecular mechanism underlying the microtubule- 
dependent nuclear accumulation of AR.
II. Determine whether AR associates with microtubules and whether it binds 
microtubules directly (in vitro) or indirectly (in cells) via partner proteins.
III. Identify the minimum microtubule-binding domain on the AR protein.
IV. Investigate the impact of taxane treatment on the trafficking of AR 
variants ARv567 and AR-V7 in terms of their nuclear accumulation and 
activity.
V. Determine whether AR variants associate with microtubules and the 
minus-end directed motor protein dynein.
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M aterials and M ethods
2.1 Cell culture, antibodies and reagents
he prostate cancer cell line, PC3 was obtained from ATCC (Manassas,
VA) and a stable cell line expressing tubulin tagged to the fluorescent 
protein, mCherry (PC3:mCherry-tub), was generated by transfecting 
pcDNA3.1-mCherry-tubulin, generously gifted by Dr. Roger Tsien (UCSD, 
CA) and selecting the cells that stably expressed the construct by neomycin 
(G418) (Cellgro, Manassas, VA). The cells were maintained in RPMI1640 
medium (Cellgro) supplemented with 10% foetal bovine serum (PBS), 100 
LU./ml penicillin plus 100 p g /p i streptomycin and 200 pg /m l G418 at 37°C 
with 5% CO2.
HEK293T cells were obtained from ATCC and cultured in DMEM 
medium supplemented with 10% FBS and 100 I.U./ml penicillin plus 100 
p g /p i streptomycin at 37°C with 5% CO2. M12 prostate cancer cell lines stably 
expressing either ARv567 (M12-ARv567) or AR-V7 (M12-AR-V7) were 
generously gifted by Dr. Stephen Plymate (University of Washington School
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of Medicine, Seattle, WA) and cultured in RPMI1640 medium supplemented 
with 5% FBS, 100 I.U./ml penicillin plus 100 p g /p l streptomycin, 0.01 pM 
dexamethasone, 10 ng /m l epidermal growth factor and 10 m l/L  insulin- 
transferrin-selenium solution at 37°C with 5% CO2.
Unless otherwise stated, all reagents used were from Sigma Aldrich (St. 
Louis, MO). For immunofluorescence the following antibodies were used: 
rabbit polyclonal anti-AR (N-21) (Pocono Rabbit Farm & Laboratory, 
Candensis, PA); mouse monoclonal anti-c-Myc (Merck, Darmstadt, Germany) 
and rat monoclonal anti-a-tubulin (Novus Biologicals, Littleton, CO). The 
following secondary antibodies were used: species-matching Alexa Fluor 488 
and Alexa Fluor 568 conjugated antibodies from Invitrogen (Carlsbad, CA). 
For the co-immunoprecipitation experiments the following antibodies were 
used: rabbit polyclonal anti-GFP (Novus) and rat monoclonal anti-a-tubulin 
(YL 1/2) (Novus). For the immunoblot assays the following primary 
antibodies were used: mouse monoclonal anti-AR 441 (Novus); rabbit 
polyclonal anti-AR (N-20) (Santa Cruz Biotechnology, Inc, Santa Cruz, CA); 
rabbit monoclonal anti-AR (EP670Y) (Abeam, Cambridge, MA) specific for the 
C-terminus of AR; rat monoclonal anti-a-tubulin (YL 1/2) (Novus); rabbit 
polyclonal anti-GFP (Abeam), mouse monoclonal anti-karyopherin a  (BD 
Biosciences, San Jose, CA), mouse monoclonal anti-FLAG M2 (Sigma Aldrich) 
and rabbit polyclonal anti-actin (Sigma Aldrich). The following secondary 
antibodies were used for immunoblotting: species-matching Alexa Fluor 680 
(Invitrogen) and IRDye 800 (Rockland) conjugated antibodies. Protease 
inhibitor cocktail tablets (including serine and cysteine proteases) were 
purchased from Roche (Indianapolis, IN). Methyltrienolone (R1881) was 
purchased from Perkin Elmer (Boston, MA). The detergent Nonidet P-40 (NP- 
40) was purchased from US Biological (Swampscott, MA). Paclitaxel was
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obtained from Sigma Aldrich and docetaxel from Sanofi Aventis (Kansas City, 
MO).
2.2 Generation of AR-truncated mutants
The full-length GFP-AR plasmid (pEGFP-Cl-AR Q22) was generously 
provided by Dr. Michael Mancini (Baylor College of Medicine, Houston, TX) 
and used as the template to generate all AR-truncated mutant constructs. All 
PCR-generated AR-truncated mutant constructs were sub-cloned into the 
expression vector pEGFP-Cl (BD Biosciences, San Jose, CA), except for AR 
540-724 and AR 725-919, which were sub-cloned into the expression vector 
p3xFLAG-CMV-14 (Sigma Aldrich).
Each AR truncated mutant was in-frame engineered onto the C- 
terminus of the GFP tag or the N-terminal of the triple Flag tag. All cloning by 
PCR was performed using AccuPrime Taq DNA Polymerase High Fidelity 
(Invitrogen), with 10 jiM forward and reverse cloning primers (IDT, San 
Diego, CA). DMSO was added in PCR reactions to a final concentration of 1% 
to facilitate the amplification of GC-rich regions. All primers were designed 
using the human AR mRNA reference sequence (GenBank NM_000044). 
Table 1 describes the sequences of the primers used to amplify the different 
AR truncations. PCR reactions were set on ice and performed in a BioRad 
iCycler thermocycler using the following conditions for the N- and C-terminal 
domains: 1 cycle 94°C dénaturation for 30 sec; 30 cycles each of 94°C 
dénaturation for 30 sec, 54-59°C annealing for 30 sec, 68°C extension for 2 min 
and hold at 4°C. For the remaining AR truncations the following PCR 
conditions were used: 1 cycle 94°C dénaturation for 2 min; 35 cycles each of 
94°C dénaturation for 30 sec, 58-62°C annealing for 30 sec, 68°C extension for 
1 min and hold at 4°C. The reaction master mix contained: 5 pi 10X
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AccuPrime buffer 1,1 ]il sense primer (10 pM), 1 pi anti-sense primer (10 pM), 
0.5 pi DMSO, 1 pi AccuPrime Taq HP, 150 ng Template DNA, and the 
remaining volume to 50 pi with dH20.
Amplicon Forward sequence Reverse sequence Amplicon 
size (bp)
1 N-terminal cgcgtcgacatggaagtgcagtta cgggatcctcacgcatgtccccg 1611
[ domain (aa 1-539)
| . • gggctg
taaggt
C-terminal cgcgtcgacatgcgtttggagact cgggatcctcactgggtgtgga
_ _ _ _ _
domain (aa 540- gccag aatagatggg
919)
! ÀR 540-724 gcacgatatcgccaccatgttgga cgcacggatccaggcaaggcct
_ _ _ _ _
i gactgccagggacc tggcccac
AR 540-558 cgcacgaattctatgttggagactg cgcacggatcctcaaggcaag
—
ccagggacc gccttggcccac
Pa r  DNA cgcacgaattctatgacctgcctga cgcacggatcctcaccctgcttc
| binding domain tctgtggag ataacatttccg
|(aa  559-624)
ARDNA cgcacgaattctatgacctgcctga cgcacggatcctcatgacactgt 315
binding domain- tctgtggag cagcttctggg
hinge region (aa
559-663)
i AR hinge region cgcacgaattctatgactctgggag cgcacggatcctcatgacactgt '  117
t (aa 625-663) cccgg cagcttctggg
AR 664-724 cgcacgaattctatgcacattgaag cgcacggatcctcaaggcaag 183
gctatgaatgtc gccttggcccac
; AR 725-919 cgcacgatatcgccaccatgggctt cgcacggatccctgggtgtgga
i .
ccgcaacttacacgtg aatagatggg
Table 1. Nucleotide sequence of primers used to amplify various regions of the AR.
Two pi of PCR product was run on a 1 or 2% agarose gel with 0.5 
pg /m l ethidium bromide to check for the right size product, visualised under 
long wave UV light. The desired fragment was isolated from the PCR reaction
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using QIAquick PCR Purification Kit from Qiagen (Valencia, CA) and the 
DNA concentration was measured by UV spectrophotometry using a 
NanoDrop ND1000 Spectrophotometer (Wilmington, DE). The NanoDrop 
technology is a full spectrum (220-750 nm) spectrophotometer that measures 1 
pi of sample loaded onto a fibre optic pedestal with high accuracy using 
surface tension alone to hold the sample in place. The pedestal then moves to 
automatically adjust for an optimal path length (0.05 mm - 1 mm). A pulsed 
xenon flash lamp provides the light source and a spectrometer utilising a 
linear charge-coupled device (CCD) array is used to analyse the light after 
passing through the sample.
2.2.1 Restriction enzyme digestion and DNA phosphatase 
treatment
N-terminal and C-terminal AR were inserted into the pEGFP-Cl vector using 
Sail and BamHI sites. The rest of AR truncation constructs were inserted into 
the vector using EcoRI and BamHI sites. EcoRV and BamHI were used to 
insert the two other AR truncation constructs into the p3XFLAG-CMV vector. 
The entire volume of the PCR product (28 pi) and 1 pg of DNA from each 
vector were double digested using 20 U of restriction enzyme (New England 
Biolabs, Ipswich, MA) in a 50 pi total volume reaction containing: 5 pi 10X 
buffer, 1 pi of each restriction enzyme, 0.5 pi 100X BSA, and dH 20 up to 50 pi. 
The reactions were carried out for 3 hr at 37°C.
The linear vector was treated with the enzyme alkaline phosphatase 
after restriction enzyme digest. Alkaline phosphatase removes phosphate 
groups normally found on the 5'- ends of DNA molecules. The linear vector 
will hence be unable to ligate into a circle, since no phosphates are available 
for the ligation reaction helping to ensure that only recombinant molecules
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are produced by vector and cDNA joining. The ligation with the target DNA 
insert can still proceed, since one phosphate is present to ligate one strand at 
each cut site. The remaining nicks in the other strands will be repaired by 
cellular mechanisms after transformation.
5' phosphatase groups were removed from linearised vector DNA 
using 0.5 U of Calf Intestinal Alkaline Phosphatase, CIP (New England 
Biolabs) into the digestion reaction for a further 1 hr at 37°C. Digested PCR 
products and vectors were purified using the QIAquick PCR Purification Kit 
(Qiagen) and quantified on the NanoDrop.
2.2.2 Ligation of insert and vector
The amounts of insert and vector to be ligated were determined using the 
molecular weight of each insert. For example, ligation of a 1611 bp size insert 
into the 4731 bp pEGFP-Cl vector at a 1:10 ratio equals 41 ng of insert and 12 
ng vector.
The digested fragments were ligated using the Quick Ligation Kit 
(New England Biolabs) at a vectorrinsert ratio of 1:10 using 12 or 50 ng of 
vector in a 20 pi reaction containing: 12 or 50 ng vector, 1:10 ratio amount of 
insert DNA, 10 pi 2X Quick Ligation Reaction Buffer, 1 pi Quick T4 DNA 
Ligase and dH 20 up to 20 pi. The reaction was allowed to go for 15 min at 
room temperature. A control reaction in which the DNA insert was replaced 
with water was also set up.
2.2.3 Transformation into DH5a competent cells
All vector DNA and ligations were transformed into E.coli DH5a bacterial 
strains (Invitrogen), including the vector only ligation as a control for
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potential background vector religation. A 50 pi aliquot of competent cells was 
thawed slowly on ice and 3 pi of each ligation mix or 100-500 ng DNA was 
added to the cells. The reaction was incubated on ice for 30 min before 
undergoing heat shock for 45 sec at 42°C and recovering on ice for 2 min. 600 
pi of Super Optimal broth with catabolite repression (SOC medium) was 
added to each tube and incubated for 1 hr at 37°C. Transformed cells were 
plated onto LB-Kanamycin (Kan) or LB-Ampicillin (Amp) agar plates 
(Invivogen, San Diego, CA) containing 50jug/ml Kan or Amp, spread, let soak 
in for a few minutes and incubated at 37°C overnight.
2.2.4 DNA isolation and confirmation of clones
Individual colonies grown on overnight plates were isolated using a sterile 
pipette tip and used to inoculate 5 ml Kan/Amp-TB cultures, which were 
incubated on a shaker at 240 rpm  overnight at 37°C followed by purification 
with QIAprep Spin Miniprep Kit or HiSpeed Plasmid Midi Kit (Qiagen) 
according to the manufacturer's instructions. DNA quality was checked by 
NanoDrop.
The success of the ligation reactions was assessed by confirming the 
presence of correctly-sized plasmids in each of the selected colonies isolated 
following bacteria transformation. A PCR was carried out directly on each 
colony using primers specific for the cloned DNA or purified DNA from each 
colony subjected to a restriction enzyme digest using enzymes that cut at each 
product's specific restriction sites. For the latter assay both of the restriction 
enzymes utilised to clone the insert as well as restriction enzymes selected to 
assess the insert's orientation were used. DNA Sanger sequence analysis was 
used to confirm the integrity of all constructs.
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2.3 Transfections, co-immunoprecipitations and Western 
blotting
Transient transfections of PC3:mCherry-tub and HEK293T cells were 
performed by electroporation using the Amaxa Nucleofector Technology 
(Lonza, Walkersville, MD) along with the optimised Kit V solution (Lonza) 
according to the manufacturer's instructions. The cells were harvested 48 hr 
after transfection and total cell protein was obtained following cell lysis in 
TNES buffer (50 mM Tris, pH  7.5, 2 mM EDTA, 100 mM NaCl, 1% NP-40) in 
the presence of protease inhibitors. Cell lysates were precleared by 
centrifugation at 14,000 rpm  at 4°C for 15 min in an Eppendorf centrifuge 
(Eppendorf, Hauppauge, NY). Total cell protein concentration of the 
precleared cell lysate was determined by BCA (bicinchoninic acid) protein 
assay (Thermo Scientific, Waltham, MA).
For Western blot analysis, 50 pg of protein were resolved on 7.5% or 
10% polyacrylamide gels (Bio-Rad, Hercules, CA), transferred onto a PVDF 
membrane (Millipore, Billerica, MA). The blots were blocked in IX TNE (1M 
NaCl, 0.2M Tris, pH  7.5, 0.05M EDTA, pH  8.0) containing 0.2% Tween-20 and 
5% nonfat dried milk and probed with primary antibodies as indicated in the 
figures. The blots were then washed 3 times in IX TNE + 0.2% Tween-20 and 
incubated with Alexa Fluor 680 or IRDye 800 secondary antibodies. 
Immunoreactive proteins were detected by Odyssey Infrared Imaging 
Technology (Li-Cor, Lincoln, NE).
For co-immunoprecipitation experiments 2 mg or more of total cell 
protein was incubated with the anti-GFP or anti-a-tubulin antibodies and 
ultralink immobilsed protein G Plus-Agarose suspension beads (Calbiochem, 
San Diego, CA) for 1 hr at room temperature. To minimise non-specific 
binding the beads were thoroughly washed 3 times for 5 min with 1 ml of a
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washing buffer (50 mM Tris-HCl, 150 mM NaCl, 0.1% NP-40, ImM  EDTA) 
and resuspended in 20 pi of IX Laemmli sample buffer. Immune complexes 
were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) and transferred onto a PVDF membrane for AR immunoblotting. 
To rule out non-specific binding of the protein of interest to the agarose beads, 
a sample identical to the immunoprécipitation sample, but without the 
addition of the antibody, was incubated with species-specific IgG and 
processed identically. In addition, 1 pg of the respective antibody used for the 
immunoprécipitation was resolved by SDS-PAGE as a control for the size of 
the heavy chains present in the sample.
For immunoblotting, antibodies AR 441, AR (N-20) both specific for 
full-length AR or N-terminus AR and AR (EP670Y) specific for the C-terminus 
were used. Rat a-tubulin (YL 1/2) (Novus) was used to detect total tubulin.
2.4 Microtubule co-sedimentation assay
The microtubule co-sedimentation assay is an assay routinely used to analyse 
proteins that specifically bind to microtubule polymers. The basic principles 
of the assay involve addition of exogenous purified microtubule protein to a 
crude cell extract which is then subjected to a cycle of polymerisation in  the 
presence of the microtubule stabilising drug paclitaxel. Tubulin is present at 
10 pM final concentration, which is the critical concentration of tubulin 
required for polymerisation and paclitaxel is present at 20 pM final 
concentration. Paclitaxel is required to induce robust tubulin polymerisation 
at 37°C and form microtubules. Any cellular proteins that have affinity for the 
microtubule polymer will co-sediment with the tubulin pellet following 
ultracentrifugation at 100,000 g. The exogenous purified microtubule protein 
serves as a substrate for proteins that have affinity for microtubule polymers
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to readily associate with. Following centrifugation the pellet (microtubules 
and associated cell proteins) and supernatant (soluble tubulin dimers and all 
other cell proteins) fractions are loaded on adjacent wells of an SDS-PAGE, 
transferred and immunoblotted for the proteins of interest.
For this experiment, PC3 :mCherry-tub or HEK293T cells transiently 
transfected with pEGFP-Cl-AR were lysed in PEM buffer (80 mM PIPES, 1 
mM MgC12, 1 mM EGTA, pH 6.9) supplemented w ith IX cocktail protease 
inhibitors and 0.5% Triton X-100. The cell lysate was precleared by 
centrifugation at 14,000 rpm  at 4°C for 15 min and the high speed 
supernantant (HSS), equivalent to a whole cell extract, was separated from the 
high speed pellet (HSP). The HSP contained cellular proteins that aggregated 
non-specifically and was not further used in the assay. The HSS was then 
subjected to the microtubule co-sedimentation assay as previously described 
(Giannakakou et al, 2000).
Briefly and as illustrated in Figure 2.1, bovine brain tubulin 
(Cytoskeleton, Denver, CO) was reconstituted with 1 mM GTP in 100 pi PEM 
buffer on ice to give a final concentration of 10 m g/m l (100 pM). 1 mg of HSS 
was incubated with 1 m g/ ml of reconstituted tubulin (10 pM), 1 mM GTP, 
and 20 pM paclitaxel and allowed to polymerise at 37°C for 30 min. Samples 
were loaded onto microcentrifuge tubes and spun at 100,000 x g at room 
temperature in an airfuge ultracentrifuge (Beckman Coulter Inc., Fullerton, 
CA). The warm supernatant (WS) was separated from the warm pellet (WP), 
which was resuspended in an equal volume of PEM buffer and sonicated 
three times for 30 sec each time. Equal volumes (30 pi) from each respective 
fraction were loaded in a 7.5% SDS-PAGE and following protein transfer 
immunoblotting was performed with antibodies against AR (1:200 dilution, 
overnight at 4°C) and a-tubulin (1:2000 dilution, 2 hr at room temperature).
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Figure 2.1 Schematic representations of the microtubule co-sedimentation assay. Paclitaxel 
is used at 20 pM to achieve effective polymerisation of microtubules at 37°C. BBMT: brain 
bovine microtubules.
Densitometry analysis for each respective protein was performed using 
Image) (National Institutes of Health) software. The percentage of protein 
present in the WP fraction was calculated using the following formula:
% WP = 100*WP/(WP/WS)
2.5 In vitro protein binding assay
Direct binding of AR to microtubules was assessed in an in vitro microtubule- 
binding assay performed with purified recombinant AR and purified bovine 
brain tubulin using the Microtubule Binding Protein Spin-down Assay Kit 
from Cytoskeleton, Inc. according to the manufacturer's instructions. Briefly, 
microtubules were assembled from 1 mg of purified brain bovine tubulin in 2
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jil of cushion buffer (80 mM PIPES pH  7.0,1 mM MgC12,1 mM EGTA in 60% 
glycerol) supplemented with 1 mM GTP at 35°C for 20 min and immediately 
stabilised in 200 pi of warm PEM (80 mM PIPES pH 7.0, 2 mM MgC12, 0.5 mM 
EGTA) containing 20 pM paclitaxel. The microtubules (5 pM tubulin) were 
incubated with 0.1, 0.2, 0.5 and 1 pg of purified His-tagged recombinant AR 
(Prolias, Frederick, MD) in a total volume of 50 pi of Buffer AR (20 mM Tris- 
C1 (pH 8.0), 20% glycerol, 100 mM KC1, 0.2 mM EDTA and 1 mM DTT) at 
room temperature for 30 min. The reaction mixtures were then centrifuged 
through a paclitaxel-supplemented cushion buffer at 100,000 x g at 25°C for 40 
min. The supernatant and pellet fractions were resuspended in 50 pi of IX 
Laemmli sample buffer and resolved on 7.5% SDS-PAGE and the presence of 
AR and tubulin was detected by immunoblot analysis. Purified MAPs at 0.64 
pM or bovine serum albumin (BSA) at 2.2 pM final concentration were also 
subjected to the microtubule-binding assay and used as positive and negative 
control, respectively. Relative protein abundance in the control reactions was 
determined by Coomassie blue staining (Invitrogen).
2.6 Immunofluorescence staining and confocal microscopy
For immunofluorescence and confocal microscopy of fixed cells the following 
protocol was used. PC3 cells stably expressing the AR (PC3-AR) were kept in 
phenol-red free, 5% charcoal-stripped media for 6 hr prior to plating on 8 mm 
glass coverslips in 24-well plates. The cells were allowed to attach overnight 
followed by treatment with the indicated drugs. The cells were fixed for 10 
min at room temperature in PHEMO buffer (68 mM PIPES, 25 mM HEPES, 15 
mM EGTA, 3 mM MgC12, 10% DMSO, pH  6.8) supplemented with 3.7% 
formaldehyde, 0.05% glutaraldehyde and 0.5% Triton X-100. Cells were 
washed in PBS three times for 5 min then blocked in 10% normal goat serum
61
M aterials and M ethods
for 10 min at room temperature. The following primary antibodies were used 
for the immunostaining: rabbit polyclonal anti-AR (N-20) 1:100 and rat 
monoclonal anti-a-tubulin 1:500, both antibodies incubated for 1 hr at room 
temperature. The secondary antibodies used were Alexa Fluor 488-conjugated 
goat anti-rabbit immunoglobin G (IgG) 1:500 and Alexa Fluor 568-conjugated 
goat anti-rat IgG 1:500. DNA was counterstained with 1 pg /m l 4, 6- 
diamidino-2-phenylindole, DAPI (Sigma Aldrich) in water for 10 min. The 
cells were mounted using Mowiol (Calbiochem, Darmstadt, Germany) and 
imaged using a Zeiss 5 LIVE confocal microscope (Thornwood, NY) with a 
63x/1.4 Plan APOCHROMAT or a 100x/1.4 Plan APOCHROMAT objective. 
All images were acquired and analysed using Zeiss LSM 5 LIVE software.
M12-ARv567 and M12-AR-V7 cells were plated on 8 mm glass 
coverslips in 24-well plates and allowed to attach overnight before being 
transiently transfected by FuGENE 6 (Roche) with a c-myc-tagged 
pCMVHSOm plasmid containing dynamitin (gifted by R. Vallee, Columbia 
University, New York, NY), used to disrupt dynein-cargo interactions. 
Twenty four hours post-transfection, the cells were fixed for 10 m in at room 
temperature in PHEMO buffer (68 mM PIPES, 25 mM HEPES, 15 mM EGTA, 
3 mM MgCh, 10% DMSO, pH 6.8) supplemented with 3.7% formaldehyde, 
0.05% glutaraldehyde and 0.5% Triton X-100. Coverslips were blocked in 10% 
normal goat serum in PBS for 10 min and processed for double-labelling 
immunofluorescence with rabbit anti-AR 1-21 (PRF&L, Canadensis, PA), rat 
anti-a tubulin and mouse anti-c-myc at the indicated concentrations. The 
secondary antibodies used were Alexa Fluor 488, 586 and 647 (1:500). DNA 
was counterstained with 1 pg /m l 4, 6-diamidino-2-phenylindole, DAPI 
(Sigma Aldrich) in water for 10 min. Coverslips were mounted using Mowiol 
(Calbiochem, Darmstadt, Germany) and imaged using a Zeiss 700 confocal
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microscope (Thornwood, NY) with a 63x/1.4 Plan APOCHROMAT objective. 
The images were acquired and analysed using Zeiss ZEN software.
MetaMorph image analysis software was used to calculate the amount 
of each variant in the nucleus from control and dynamitin-expressing cells 
from a sum projection assembled from all the z-stacks. Nuclear AR-variant 
values were obtained using integrated pixel intensity values from the sum 
projection and the percentage of nuclear AR was calculated using the 
following formula:
% Nuclear AR = 100*Nuclear AR/Total AR
The p-values for AR-variant nuclear localisation in control and 
dynamitin-expressing cells were calculated using a two-tailed t-test with 
equal variances.
2.7 Live cell imaging of AR intracellular trafficking
For live cell imaging experiments, PC3:mCherry-tub cells were plated on 
MatTek (Ashland, MA) 5 mm, Poly-d-lysine coated glass bottom dishes No. 
1.5. Cells were pressure-microinjected intranuclearly with cDNA in HKC1 (10 
mM HEPES, 140 mM KC1, pH 7.4) using a Narishige micromanipulator 
(Narishige, Greenvale, NY). The concentration of GFP-AR cDNA in the needle 
was 20 jig/ml. After injection, cells were transferred to phenol-red free, 5% 
charcoal-stripped media and maintained at 37°C for 2 hr to allow for 
expression of GFP-AR. Cells were transferred to a live cell chamber and 
maintained at 37C and 5% C02 using the Tokai Hit Temperature control unit 
INUG2-ZILCS (Shizuoka, Japan). R1881 was added to the cells using a Tokai 
Hit perfusion pipe/tube set with Luer lock syringe.
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Time-lapse images were taken using a Spinning Disk microscopy 
system consisting of a Zeiss Axiovert 200 system fitted with a Yokogawa 
CSU-X1 spinning disk head (Tokio, Japan). GFP-AR images were acquired at 
10 min intervals for 2 hours with a 63x/1.4 Plan APOCHROMAT objective 
and collected with an ORCA R2 camera (Hamamatsu Photonics, Japan). For 
analysis of GFP-AR trafficking in PC3:mCherry-tub cells, image stacks (0.5 jim 
Z-sections through the entire cell depth) were acquired at each time point. 
The devices were controlled with the Zeiss AxioVision software. AxioVision 
files were saved as 16-bit images and exported to MetaMorph. Background 
subtraction was performed using the mean pixel value of a non-cell region on 
each image with the statistical correction function in MetaMorph and a sum 
projection was assembled from the images recorded at 10 min intervals. High- 
intensity pixels in noncellular regions or regions not of interest were also 
scaled out. Nuclear versus cytoplasmic AR values were obtained using 
integrated pixel intensity values from the sum projection and the percentage 
of nuclear AR was calculated using the following formula:
% Nuclear AR = 100*Nuclear AR/Total AR
The p-values for AR nuclear localisation in control, taxane- and 
nocodazole-treated cells were calculated using one-way analysis of variance 
(ANOVA) followed by multiple comparisons with Bonferroni adjustments 
using Stata Statistical Software: release 10.
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Results
3.1 Taxane treatment impairs AR nuclear accumulation
O test the hypothesis that the microtubule cytoskeleton mediates AR's
nuclear transport, the effects of taxane treatment on the nuclear 
accumulation of AR were examined. For this experiment PC3 cells were stably 
transfected with AR (PC3-AR). The prostate cancer PC3 cell line is androgen- 
independent and doesn't express the androgen receptor, therefore mimicking 
clinical disease progression as prostate cancer goes from an androgen- 
sensitive state to castration-resistance. PC3-AR cells were treated w ith the 
synthetic DHT analogue R1881 to induce ligand-dependent nuclear 
translocation of AR in the presence or absence of 50 nM docetaxel (DTX). 
R1881 has an affinity Kd of 2.3 nM for the AR, similar to its natural ligand, 
DHT (Kd = 2 nM) (Murthy et al, 1986). The optimal docetaxel concentration 
was determined based on the steady state serum levels of taxanes ranging 
from 75 to 150 nM at 24 hr post administration (Brunsvig et al, 2007). The cells
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AR Tubulin Merge
Control
R1881
DTX + R1881
Figure 3.1 Taxane treatment impairs AR nuclear accumulation. PC3-AR cells were treated 
with either InM  R1881 for Ih r or with R1881 following 50 nM docetaxel (DTX) pretreatment 
for 4 hr. Cells were then fixed and double-labelled for immunofluorescence of AR (green) and 
total tubulin (red). The DNA stain DAPI is shown in blue in the merged images. Arrows 
point to AR nuclear localisation and arrow head points to perinuclear microtubule bundles. 
All images are representative and were obtained by high-resolution confocal microscopy.
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were then fixed and processed for double-labelling immunofluorescence for 
AR and total tubulin and imaged using high- resolution confocal microscopy. 
The results in Figure 3.1 show that, as expected, R1881 treatment (1 nM for 1 
hr) robustly induced the nuclear accumulation of AR. However, w hen cells 
were exposed to docetaxel (50 nM for 4 hr) prior to ligand stimulation, AR 
was confined to the cytoplasm. This effect was consistent with the docetaxel- 
induced stabilisation and bundling of the microtubule cytoskeleton, as can be 
visualised in the figure by the red tubulin perinuclear bundles (white arrow 
head) in contrast to the fine and intricate microtubule network present in the 
R1881 treated cells. This experiment indicated that AR nuclear accumulation 
requires intact microtubules. This result, together with the role of 
microtubules in intracellular transport of some hormone receptors and 
transcription factors, prompted the investigation of the microtubule- 
dependent transport of AR. The effect of taxane treatment on expression of 
downstream targets of AR was looked at in dose-dependent studies carried 
out in the lab as part of this project. AR transcriptional activity using a 
luciferease reporter assay to PSA was carried out in LNCaP cells expressing 
endogenous AR. The results, described in Darshan et al, 2011, show that 
taxane treatment with 25 or 50 nM paclitaxel inhibited AR transcriptional 
activity in a dose-dependent manner consistent with the observed drug- 
induced AR nuclear exclusion. Similarly, docetaxel treatment also decreased 
the secretion of PSA in a dose-dependent manner measured in conditioned 
media collected from LNCaP cells treated with 25 or 50 nM of docetaxel.
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3.2 Dynamics of microtubule-dependent AR nuclear 
translocation
Live cell confocal microscopy was performed to investigate the dynamics of 
AR nuclear accumulation in relation to drug-induced perturbations of 
microtubule dynamics. For this experiment, PC3 cells stably expressing 
tubulin fused to the fluorescent protein mCherry (mCherry-tub) were used 
for purposes of visualisation of the microtubule cytoskeleton. PC3:mCherry- 
tub cells were microinjected with wild-type AR fused to green fluorescent 
protein (GFP-AR). The goal of the experiment was to monitor in real-time the 
dynamics of ligand-induced nuclear translocation of AR in living cells in the 
presence or absence of taxane treatment. For this experiment R1881 was used 
as the AR ligand and microtubule disruption was achieved using paclitaxel 
(PTX) at 1 pM concentration to achieve maximal drug-target effect, i.e. to 
stabilise cellular microtubules, and nocodazole (Noc), a microtubule 
depolymerising agent, at 10 pM. Even though nocodazole is not a drug used 
for the clinical management of CRPC, its use in the live cell imaging 
experiments strengthens the role of microtubules in the cellular transport of 
AR. Paclitaxel is used in the clinic for CRPC patients that show disease 
progression while on docetaxel. However, the preferred taxane, and the one 
used in subsequent experiments is docetaxel since this taxane is FDA 
approved as first-line treatment of CRPC patients.
Microinjected cells were incubated for 2 hr to allow for GFP expression, 
in charcoal-stripped media, which does not contain any steroids, during 
which time either paclitaxel or nocodazole was added. After the drug 
pretreatment, GFP-AR cells were identified under the microscope's eye piece 
and marked as a position. Time-lapse images of each position were acquired 
at baseline and at 10 min intervals following ligand addition for a total of 2 hr.
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Figure 3.2 Dynamics and quantitation of AR nuclear accumulation using live cell imaging.
A:maximum intensity projection of PC3:mCherry-tub cells transfected with wild-type GFP- 
AR treated with the DHT analogue R1881 InM  in the absence or presence of IpM  paclitaxel 
(PTX) or 10 pM nocodazole (Noc). Time lapse images were obtained at 10 min intervals for 2 
hr. Representative cells are shown at the indicated timepoints. The integrity of the 
microtubule cytoskeleton was visualised at the beginning of the timelapse and is shown in 
the far right panels. Solid arrow points at a fine microtubule network, arrowhead points at 
microtubule bundles and dashed arrow points at soluble tubulin. B: Quantitation of nuclear 
GFP-AR(wt) over time following each treatment was performed using integrated pixel 
intensity values from the sum projection. N values: Control 0,10 and 20 min: n=8; 30-110 min: 
n=7; 120 min: n=6. PTX pretreated 0-80 min: n=12; 90 min: n=8; 100, 110 and 120: n=3. One­
way ANOVA with equal variances followed by multiple comparisons with Bonferroni 
adjustments.
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The entire volume of individual cells was imaged at 0.5 jim intervals along 
the z-axis (z-stack) and each z-stack was compressed into maximum intensity 
projections as shown in Figure 3.2. Following as little as 20 min of R1881 
treatment, GFP-AR rapidly accumulated to the nucleus reaching a maximum 
at 60 min post-treatment. By sharp contrast, both paclitaxel and nocodazole 
pretreatment impaired the ability of AR to accumulate to the nucleus, 
consistent with their effects on microtubule disruption, as seen by the images 
on the far right panels in Figure 3.2 that show the microtubule cytoskeleton.
In certain cells AR was entirely confined to the cytoplasm, unable to 
translocate to the nucleus following ligand stimulation while others displayed 
very slow kinetics of AR nuclear accumulation. To quantitate the rate of AR 
nuclear accumulation in untreated, paclitaxel- or nocodazole-pretreated cells, 
image analysis using MetaMorph software was performed. In this type of 
analysis a sum projection of all the z-stacks was put together, the background 
subtracted from each frame and pixel intensity values used to determine the 
percentage of nuclear versus cytoplasmic AR. A one-way ANOVA followed 
by multiple comparisons with Bonferroni adjustments was performed to 
calculate the p value for AR nuclear accumulation of control and paclitaxel- or 
nocodazole-pretreated cells at each timepoint. The results of this analysis are 
graphically displayed in Figure 3.2 B and clearly show that the amount of 
nuclear AR is significantly lower in paclitaxel- and nocodazole-treated cells as 
compared to the untreated, control cells (p<0.01-0.001). The results from fixed 
and live cell confocal microscopy indicate that the nuclear accumulation of 
AR requires the presence of an intact, non-perturbed microtubule 
cytoskeleton.
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3.3 AR associates with microtubules
The previous results suggest that AR's subcellular localisation and trafficking 
occur in a microtubule-dependent manner, implying a direct or indirect 
interaction between AR and microtubules. To confirm the association between 
AR and microtubules at the biochemical level, co-immunoprecipitation (co-IP) 
assays were performed. Whole cell lysates (WCL) from PC3:mCherry-tub cells 
transfected with wild-type (wt) GFP-tagged AR were subjected to co-IP with 
either an anti-a-tubulin or an anti-GFP antibody. The immunoprecipitates 
were then resolved by SDS-PAGE and immunoblotted with antibodies 
against AR, GFP or tubulin. Figure 3.3 A and B show that AR co-precipitates 
with tubulin, while tubulin was found to co-precipitate with the GFP-tagged 
AR protein in the GFP-immunoprecipitation. Immunoprécipitation of WCL 
with IgGs specific for each antibody, did not pull down AR or tubulin, 
respectively, confirming the specificity of the association between AR and 
tubulin.
To further investigate whether AR associates preferentially with the 
microtubule polymer or with soluble tubulin dimers, a microtubule co­
sedimentation assay was performed in the presence or absence of the 
synthetic AR ligand, R1881. In this experiment, exogenous purified bovine 
brain tubulin protein is added to cell lysates in PEM buffer, a buffer that 
favours microtubule polymerisation, and subjected to a cycle of 
polymerisation at 37°C in the presence of 20 pM paclitaxel for 30 min. 
Microtubule polymers and any cellular proteins with affinity for them will co­
sediment in the warm  pellet (WP) fraction following polymerisation and high 
speed centrifugation, while any soluble tubulin and other proteins that do not 
have affinity for the microtubule polymer will segregate with the warm  
supernatant (WS). Equal volumes from each of the fractions were loaded onto
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Figure 3.3 AR associates with microtubules. A and B: Co-IP of whole cell lysates (WCL) from 
PC3:mCherry-tub cells transfected with GFP-tagged wild-type AR immunoprecipitated with 
either anti-rat a-tubulin antibody or rat IgG (A) and anti-rabbit-GFP or rabbit IgG (B) as a 
control for specificity. 50 pg of control WCL not subjected to immunoprécipitation were also 
loaded in the indicated lanes. Blot was immunostained with specific antibodies against AR 
and tubulin. 1 jug of the antibody used for the IP was also loaded as a control for the antibody 
heavy chains. C. A microtubule co-sedimentation assay using whole cell lysate from 
PC3:mCherry-tub cells transfected with GFP-tagged wild-type AR (GFP-AR(wt)) was carried 
out in the presence or absence of the synthetic DHT analogue (R188110 nM) to assess binding 
to the microtubule polymer. Briefly, a total of 1 mg of precleared cell extract (HSS) from the 
transfected cells was incubated for 30 minutes with 10 pM exogenous purified bovine brain 
tubulin and subjected to a cycle of polymerisation with 20 pM paclitaxel at 37°C. The samples 
were centrifuged at 100,000 g to separate the microtubule polymers (WP) from the soluble 
tubulin dimers (WS), resolved by SDS-PAGE and immunoblotted for the presence of AR, 
tubulin and actin. HSS: high speed supernatant; HSP: high speed pellet; WP: warm pellet; 
WS: warm supernatant. D: PC3:mCherry-tub cells were subjected to immunoprécipitation 
using an anti-rat a-tubulin antibody or matching rat IgG. Immunoprecipitates were resolved 
on SDS-PAGE along with 50 pg of WCL not subjected to immunoprécipitation and 
immunoblotted with an antibody against im portin-al (karyopherin a2).
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adjacent wells of an SDS-PAGE, resolved and immunoblotted with antibodies 
against AR, tubulin and actin.
As seen in Figure 3.3 C, the majority of tubulin was successfully 
polymerised (large band in WP), while AR co-fractionated mostly with the 
microtubule polymer in the absence of its ligand. Quantitation of the amount 
of AR and tubulin in the WP fractions was calculated based on the intensity of 
each band assessed by densitometry. So, the amount of protein in the WP is 
calculated over the total amount of the polymerised and soluble fractions 
using the following formula: %WP = 100*WP/ (WP/WS). Densitometry 
analysis showed that while 85% of AR was found in the WP in the absence of 
the synthetic ligand, R1881, when the AR was stimulated w ith R1881, a shift 
to the WS was seen and only 40% of AR co-sedimented in the WP fraction 
indicating less association with the microtubule polymer. As a negative 
control the same blot was probed for actin, which did not co-sediment with 
the microtubule polymer fraction. These results clearly show that full-length 
AR preferentially associates with the microtubule polymer over tubulin 
dimers and that this association is diminished in the presence of AR ligand. 
Furthermore, it is known that importin-a binds to the AR NLS to mediate its 
nuclear import (Cutress et al, 2008). Therefore, the association between 
importin-a and cellular microtubules was investigated. As shown in Figure 
3.3 D, tubulin co-precipitation brought down importin-a, suggesting that 
microtubules serve as the scaffold where AR associates with importin-a for its 
efficient and directed nuclear import. These results indicate an association 
(direct or indirect) between AR and tubulin, thus corroborating and extending 
the results shown in Figure 3.1 and lends further support to the role of 
microtubules as tracks for AR transport toward the nucleus as seen in Figure 
3.2.
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3.4 AR binds directly to microtubules
To investigate whether AR binds microtubules directly or via accessory 
proteins, an in vitro binding assay using purified bovine brain tubulin and 
purified recombinant His-tagged AR was performed. As in the microtubule 
co-sedimentation assay, this assay was performed with purified proteins 
instead of cell lysates and relies on the fact that microtubule polymers will 
sediment in the pellet when centrifuged at 100,000 g. Therefore, any protein 
that binds microtubules is expected to co-sediment with the pellet fraction 
following centrifugation. Identification of the protein of interest in the pellet 
fraction determines whether a protein binds to microtubules in a cell-free 
system. For this experiment, 1 pg of purified recombinant His-AR was 
initially incubated with preformed microtubules in PEM buffer, as previously 
described. Purified bovine brain MAPs and BSA proteins were also included 
in the binding assay, as a positive and negative control for microtubule 
binding, respectively. Furthermore, in order to specifically rule out any non­
specific binding of AR to microtubules, self-aggregation of AR in the absence 
of microtubule protein was assessed under the assay conditions.
The conditions needed to keep AR soluble (in the supernatant) in the 
absence of microtubules were optimised using different amounts of purified 
AR and a "mock" binding assay with an AR protein gradient of 0.1, 0.2 and 
0.5 pg was performed. As can be seen from Figure 3.4 A, AR (at 1 pg) 
sedimented in the pellet (P) fraction in the absence of microtubules in PEM 
buffer. In addition, the effect of the two different buffers on aggregation or 
dénaturation of the AR protein that resulted in its non-specific sedimentation 
was examined by testing both Buffer AR (supplied with the recombinant AR) 
and PEM buffer, commonly used for tubulin polymerisation. The results of 
this experiment are depicted in Figure 3.4 B and show that when AR was used
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Figure 3.4 In vitro binding of AR to microtubules. A: Direct binding of AR to microtubules 
was assessed using an in vitro microtubule-binding assay. Briefly, 1 pg of purified 
recombinant AR was incubated with preformed microtubules in PEM buffer and subjected to 
a cycle of polymerisation at 37°C in the presence of paclitaxel. AR co-sedimented in the pellet 
in the absence of microtubules in PEM buffer. B: 0.1, 0.2 and 0.5 pg of AR were used to assess 
how much AR will remain in the supernatant in the absence of microtubules and a "mock" in 
vitro binding assay carried out in both PEM buffer and Buffer AR. C: The assay was repeated 
in Buffer AR using 0.1 pg of AR and AR was found to bind directly to microtubules. 
Microtubule polymerisation was successful as seen by the majority of tubulin in the pellet (P) 
fractions. D: Positive and negative microtubule-binding controls, MAP and BSA (in Buffer 
AR) were detected by Coomassie staining after being subjected to an in vitro binding assay 
with tubulin. M: protein marker (sizes in KDa).
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at low amounts (0.1 and 0.2 jig) the majority of AR protein remained in the 
soluble fraction (S) using Buffer AR. This was not the case w ith PEM buffer, 
where the AR pelleted (P) even at the lowest amount. This result indicated 
that the protein was not denatured but that at high amounts it is able to pellet 
on its own when subjected to ultracentrifugation.
Based on these results, 0.1 pg of AR was chosen to perform the in vitro 
microtubule binding assay in Buffer AR. The results in Figure 3.4 C show that 
while the majority of AR protein remains in the supernatant (S) in the absence 
of tubulin, in the presence of microtubules, most of AR protein is shifted from 
the supernatant to the pellet fraction confirming that it binds directly to 
microtubule polymers. Furthermore, as seen in the lower blot of the figure, 
tubulin was able to polymerise efficiently in Buffer AR, as demonstrated by 
the fact that the majority of the purified tubulin sedimented in the pellet 
fraction (P) as expected at high speed centrifugation in the presence of 
paclitaxel.
In order to assess the efficacy and sensitivity of the in vitro binding 
assay, the microtubule-binding ability of positive and negative microtubule- 
binding controls, MAP (MAP2 and tau) and BSA was determined by carrying 
out an in vitro binding assay with tubulin and each one of these proteins. 
Once again, the pellet and supernatant fractions were separated by SDS- 
PAGE and detection of tubulin, MAP and BSA was carried out by Coomassie 
staining.
As expected and shown in Figure 3.4 D, the MAP protein, which 
migrates at 280 kDa, appeared in the pellet (P) fraction in the presence of 
microtubules and in the supernatant (S) fraction in their absence, while BSA, 
which migrates at 68 kDa, appeared in the supernatant fraction in both cases.
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3.5 Identification of the minimum microtubule-binding domain
The results so far show that AR protein associates with microtubules and 
traffics on them for its efficient nuclear targeting. Therefore, the minimum 
domain, or portion of the AR that is responsible for the binding to 
microtubules was investigated. To identify the minimum AR domain 
required for microtubule binding, deletion mutants of the AR were generated 
using PCR-based sub-cloning. Two major deletion mutants were generated 
and sub-cloned into the expression vector pEGFP-Cl: the N-terminal domain 
(N-ter, aa 1-539) encompassing exon 1 of the AR cDNA and the C-terminal 
domain (C-ter, aa 540-919) encompassing the DNA binding domain, the hinge 
region and the LBD of AR represented schematically in Figure 3.6 A.
Figure 3.5 shows the cloning process performed by sticky-end cloning 
of PCR products. Primers specific to the sequences to be amplified were 
designed with restriction enzyme targets sites for Sail and BamHI, introduced 
into each of the primers. The resulting PCR products (Figure 3.5 A) for the bi­
ter (1611 bp) and C-ter (1143 bp) AR as well as the cloning vector (pEGFP-Cl) 
were digested with Sail and BamHI to generate complementary ends, which 
were then ligated, transformed into DH5a competent cells and plated on Kan- 
agar plates. Colonies from each plate were picked and a diagnostic digest 
with Sail and BamHI was carried out to confirm the size of the inserts. 
Digestion of pEGFP-Cl-AR-N-ter with these enzymes should produce two 
fragments of 1600 bp and 4700 bp in size, whereas digestion of pEGFP-Cl- 
AR-C-ter should produce two fragments of 1200 bp and 4700 bp in size. As 
seen from Figure 3.5 C, six out of eight colonies from pEGFP-Cl-AR-N-ter 
and all seven colonies from pEGFP-Cl - AR-C-ter gave the right size 
fragments, and were subsequently sent for Sanger sequencing for verification.
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Figure 3.5 Generation of N- and C-terminal AR. A: AR truncations N-terminal and C- 
terminal were sub-cloned into a pEGFP-Cl vector and a 1% agarose gel was used to run the 
fragments to check for correct size (AR N-ter: 1611 bp; AR C-ter: 1143 bp). B: The pEGFP-Cl 
vector and all inserts were double digested with Sail and BamFlI for 3 hr at 37°C and the 
vector treated with alkaline phosphatise for an additional hour at 37°C before being purified, 
ligated and transformed into DH5a competent cells. C: A diagnostic double digest with Sail 
and BamHI was carried out on midipreps from 8 colonies from the AR N-ter plate and 7 
colonies from the AR C-ter plate and run on a 1 % agarose gel. All AR C-ter clones and six out 
of eight AR N-ter clones were positive. All positive clones were sent for DNA sequencing for 
verification. L: 1 kb DNA ladder.
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Once the sequence of each truncation was confirmed, illustrated 
relative to the wild-type AR in Figure 3.6 A, a co-IP experiment was carried 
out to determine whether they associate with tubulin. Each truncation was 
transiently transfected into PC3:mCherry-tub cells, whole cell lysates 
extracted and subjected to co-IP with an anti-tubulin antibody. As a positive 
control for the co-IP assay the same cell line was used to transiently transfect 
the wild-type GFP-tagged AR (GFP-AR(wt)) and whole cell lysate from non­
transfected PC3 : mCherry-tub cells was used as a negative control.
The co-IP showed that wild-type AR associated with tubulin, as 
expected, and so did N-ter AR as well as the C-ter AR protein. While the 
amount of C-ter AR that co-precipitated with tubulin was significantly higher 
than that of the N-ter AR (by comparing the relative amounts of WCL present 
in each respective lane), this experiment didn't discriminate between the two 
halves of AR protein and given the weak signal obtained with the C-ter-AR 
co-IP, a microtubule co-sedimentation assay was carried out as the more 
sensitive method to assess the binding ability of either fragment with the 
microtubule polymer in two different cell lines (Figure 3.7). Briefly, 
PC3imCherry-tub (A) or HEK293T cells (B) were transiently transfected w ith 
either GFP-tagged wild-type AR (GFP-AR(wt)), as a positive control for 
microtubule binding, GFP-tagged N-ter AR or GFP-tagged C-ter AR and 
subjected to a microtubule co-sedimentation as described earlier.
The results in Figure 3.7 A and B show that in both cell lines, the 
second half of AR, the C-ter mediates microtubule binding, as it sediments 
with polymerised tubulin in the WP fraction in contrast to the first half of AR, 
the N-ter, the majority of which co-fractionated with the pool of soluble, non­
polymerised tubulin (WS). Densitometry analysis showed that only 13% of 
the N-ter AR was found in the WP in contrast to 86% of the C-ter AR. Similar
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Figure 3.6 Association of AR truncations with tubulin. A: Schematic representation of two 
AR truncations generated by PCR-based cloning and subcloned onto the C-terminus of the 
GFP tag in the pEGFP-Cl vector. N-terminal AR (N-ter AR) comprising of exon 1 from the 
AR cDNA; C-terminal AR (C-ter AR) comprising of exons 2-8. B: Tubulin co- 
immunoprecipitation assay was carried out on 1 mg of PC3:mCherry-tub cells transiently 
transfected with either GFP-tagged wild-type AR (GFP-AR(wt), GFP-tagged N-ter AR (GFP- 
N-ter-AR) or GFP-tagged C-ter AR (GFP-C-ter-AR) using an anti-rat tubulin antibody or 
matching species IgG. 50 gg of untrasfected PC3:mCherry-tub cells (Pc3mCh) and 50 gg of 
control whole cell lysate (WCL) from transfected cells not subjected to immunoprécipitation 
were loaded in the indicated lanes as well an antibody control (TUB Ah) to detect heavy 
chains coming from the antibody. The blot was immunostained with specific antibodies 
against each AR truncation and tubulin.
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Figure 3.7 Microtubule-binding is mediated by the C-terminal domain of AR.
PC3:mCherry-tub (A) or HEK293T cells (B) were transiently transfected with full-length GFP- 
AR(wt), GFP-N-ter-AR or GFP-C-ter-AR and subjected to a microtubule co-sedimentation as 
described earlier. Proteins from each respective fraction were resolved on SDS-PAGE and 
immunoblotted with the indicated antibodies. Wild-type and C-terminus-AR co-fractionated 
with the microtubule pellets (WP). Tubulin was detected in as microtubules in the WP in each 
condition.
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results were obtained in both cell lines. Tubulin was efficiently polymerised 
as shown by the majority of tubulin found in respective WP fractions.
3.6 Microtubule association and trafficking of novel AR splice 
variants
The results so far show that AR associates with microtubules and that the 
binding of AR to the microtubule is mediated by the C-terminal domain of 
AR (aa 540-919). Furthermore, drugs that disrupt the normal function of the 
microtubule cytoskeleton by either stabilisation or depolymerisation, such as 
the taxanes and nocodazole, respectively, impair the nuclear accumulation of 
AR in androgen-stimulated prostate cancer cells. Recently, constitutively 
active AR splice variants have been reported in human prostate cell lines, 
xenografts and human tissues, including splice variants ARv567 (Sun et al, 
2010) and AR-V7 (Guo et al, 2009; Hu et al, 2009). AR-V7 contains the first 
three exons of the AR and a cryptic exon comprising 16 amino acids, which 
gives it a unique termination sequence. ARv567 occurs as a result of exon 4 
being spliced to exon 8, thus exons 5,6 and 7 have been deleted (Figure 3.8 A). 
This variant was found to be present in 59% of GRPC patients following 
castration and may play a role in the development of CRPC (Sun et at, 2010).
To determine whether these clinically relevant AR splice variants 
associate with microtubules similar to the full-length AR, a microtubule co­
sedimentation assay was performed in cells transiently transfected with 
plasmids encoding each of the variants. PC3:mCherry-tub cells were 
transfected with HA-tagged ARv567 (HA-ARv567) or GFP-tagged AR-V7 
(GFP-AR-V7). GFP-tagged wild-type AR and C-ter AR were used as positive 
microtubule-binding controls for these experiments. The results shown in 
Figure 3.8 B and C show that variant ARv567 retains the ability to associate
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Figure 3.8 ARv567, but not AR-V7, associates with the microtubule polymer. (A) Schematic 
representation of full-length AR as well as the splice variants ARv567, encoding exons 1-4 
and the first 10 amino acids of exon 8, and AR-V7, encoding exons 1-3 and a cryptic exon of 
16 amino acids. (B and C) A microtubule co-sedimentation assay using whole cell lysate from 
PC3:mCherry-tub cells transiently transfected with GFP-tagged wild-type AR, GFP-C-ter-AR, 
HA-ARv567 and GFP-AR-V7 was carried out to test the affinity of these variants for the 
microtubule polymer. Proteins from each of the fractions were immunoblotted with anti-AR, 
anti-tubulin and anti-actin antibodies. Wild-type AR and C-ter-AR were used as positive 
controls of microtubule-binding. Tubulin was detected as micro tubules in the warm pellet 
(WP) in each condition. Actin was used as a negative control for microtubule binding.
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with microtubules. Note the association of ARv567 w ith microtubule 
polymers (WP), which was shown to be 83% in the WP by densitometry 
analysis. In contrast, there is a marked decrease in the association of AR-V7 
with the microtubule polymer with only 40% of AR-V7 in the WP. To rule out 
non-specific sedimentation of each of the variants in the microtubule pellets, 
the same blots were reprobed for actin, which segregated in the warm 
supernatant (WS) fraction.
These results suggest that the transport of the ARv567 variant but not 
that of AR-V7 is microtubule-dependent. To test this hypothesis, the effects of 
microtubule-targeting drugs on ARv567 and AR-V7 nuclear accumulation in 
PC3:mCherry-tub cells were investigated. In order to ascertain the role of 
microtubules in ARv567 nuclear translocation, the cells were microinjected 
with GFP-tagged ARv567 and subsequently treated with either 1 juM 
docetaxel (DTX) or 10 gM nocodazole (Noc) prior to being analysed for 
evidence of docetaxel-induced microtubule bundling or nocodazole-induced 
microtubule depolymerisation by real-time confocal microscopy. The cells 
were incubated with each drug for 2 hr, during which time the GFP-ARv567 
plasmid was expressed, and followed for a 2 hr timelapse experiment with 
full z-stack images taken every 10 minutes.
Representative images are shown in Figure 3.9 A for ARv567 nuclear 
trafficking. Interestingly, although the docetaxel or nocodazole treatments did 
not change the rate of ARv567 trafficking during the 2 hr timecourse, the 
amount of ARv567 found in the nucleus at baseline (time 0) was significantly 
attenuated when compared to control (no drug pretreatment), suggesting that 
intact microtubules are key to the variant's nuclear accumulation. 
Furthermore, quantitation of the extent of either docetaxel- or nocodazole- 
induced ARv567 nuclear exclusion, seen in Figure 3.9 B, revealed a significant
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Figure 3.9 Dynamics and quantitation of ARv567 nuclear accumulation using live cell 
imaging. A: Time lapse images were obtained at 10 min intervals for 2 hr for control, 1 |iM 
docetaxel-(DTX) and 10 |iM nocodazole-(Noc) pretreated cells. Representative cells are shown 
at the indicated time points. The integrity of the microtubule cytoskeleton was visualised at 
the beginning of the timelapse recording and is shown in the far right panels. Solid arrow 
points at a fine microtubule network, arrowhead points at microtubule bundles and dashed 
arrow points at soluble tubulin. B: Quantitation of nuclear GFP-ARv567 over time following 
each treatment was performed using integrated pixel intensity values from the sum 
projection. N values: Control 0,10, 20 and 30 min: n=16; 40-120 min: n=15. DTX pretreated 0- 
80 min: n=12; 90-120 min: n=10. Noc pretreated 0-50 min: n = ll; 60-110 min: n=10; 120 min: 
n=3. One-way ANOVA with equal variances followed by multiple comparisons with 
Bonferroni adjustments.
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decrease in the nuclear accumulation of ARv567 at all time points, measured 
by one-way ANOVA followed by multiple comparisons with Bonferroni 
adjustments (p<0.01 at baseline and p<0.001 at all other time points).
The difference at baseline in AR nuclear localisation between wild-type 
AR and ARv567 is clear with almost 60% of ARv567 found in the nucleus in 
contrast to 25% of wild-type AR. Furthermore, the profound cytoplasmic 
sequestration at baseline of ARv567 following either docetaxel or nocodazole 
treatment shows that microtubule targeting drugs impair the nuclear 
accumulation of ARv567 implying that microtubules are involved in the 
shuttling of the receptor from the cytoplasm to the nucleus. The state of the 
microtubules was also observed in the cells prior to the image acquisition and 
represented in the right panels of the figure indicating effective drug-target 
engagement for each of the conditions. The results suggest that taxanes could 
inhibit ARv567 signalling by preventing ARv567 nuclear accumulation.
The other clinically relevant and constitutively active AR splice variant, 
AR-V7, was compared to the ARv567 variant in terms of microtubule- 
dependent trafficking. Live cell confocal imaging was carried out in 
PC3:mCherry-tub cells microinjected with GFP-tagged AR-V7 and treated 
with 1 gM docetaxel or 10 jliM nocodazole for 2 hours, in which time the GFP- 
AR-V7 was expressed. A timecourse experiment was set up with full z-stack 
images being acquired every 10 minutes for a duration of 2 hours following 
the drug pretreatment. Representative images of the AR-V7 trafficking are 
shown in Figure 3.10 A. The state of the microtubules was also observed in 
the cells prior to the image acquisition and represented in the right panels of 
the figure indicating effective drug-target engagement for each of the 
conditions. In contrast to what was seen for the microtubule-dependent 
ARv567 nuclear trafficking, pretreatment of the GFP-AR-V7-transfected cells
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Figure 3.10 Dynamics and quantitation of AR-V7 nuclear accumulation using live cell 
imaging. A: Time lapse images were obtained at 10 min intervals for 2 hr for control, 1 (iM 
docetaxel-(DTX) and 10 gM nocodazole-(Noc) pretreated cells. Representative cells are shown 
at the indicated time points. The integrity of the microtubule cytoskeleton from each 
condition was visualised with mCherry-tubulin at the beginning of the timelapse recording 
and is shown in the far right panels. Solid arrow points at a fine microtubule network, 
arrowhead points at microtubule bundles and dashed arrow points at soluble tubulin. B: 
Quantitation of nuclear GFP-AR-V7 over time following each treatment was performed using 
integrated pixel intensity values from the sum projection. N values: Control 0-120 min: n=9. 
DTX pretreated 0-120 min: n=9. Noc pretreated 0-100 min: n=2l, 110-120 min: n=7.
Results
with microtubule targeting drugs had no effect on the amount of AR-V7 
found in the nucleus at baseline. The levels of AR-V7 remained unchanged in 
between conditions and for the entire duration of the timelapse as seen in 
Figure 3.10 B indicating that this specific variant is not under the control of 
microtubules for its nuclear localisation.
3.7 ARv567 trafficking to the nucleus is mediated by the 
microtubule-motor protein dynein
The minus-ended microtubule motor protein dynein, has been implicated in 
the transport of nuclear receptors such as the GR (Harrell et al, 2004) and the 
PTHrP (Lam et al, 2002) as well as tumour suppressors such as p53 
(Giannakakou et al, 2000) and Rb (Roth et al, 2007). In order to drive 
subcellular motile functions, dynein works in concert with several accessory 
proteins including dynactin, an adapter that mediates the binding of dynein 
to cargo structures enhancing the motor's function. Overexpression of the 
dynactin associated protein, dynamitin, which disrupts dynein-cargo 
interactions (Burkhardt et al, 1997), was used to dissect the involvement of 
dynein in the transport of the AR splice variants to the nucleus.
The M12 prostate cancer cell line, a tumourigenic cell line, 
representative of the metastatic stage of prostate cancer, was used for these 
experiments. Stable M12 cells expressing either ARv567 (M12-ARv567) or AR- 
V7 (M12-AR-V7) were obtained from Dr. Stephen Plymate and were used to 
transiently transfect a c-myc-tagged p50-dynamitin vector. Twenty four hours 
post-transfection the cells were fixed and processed for double-labeling 
immunofluorescence with anti-AR and anti-c-myc antibodies. Overexpression 
of dynamitin (Figure 3.11 A and B) impaired nuclear accumulation of ARv567 
but had no effect on the nuclear accumulation of AR-V7. The amount of each
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Figure 3.11 ARv567, but not AR-V7, is dynein-dependent for its nuclear trafficking. A and
B: M12-ARv567 and M12-AR-V7 cells were transiently transfected with pCMVHSOmyc 
(encoding a c-myc tagged human dynamitin). Cells were fixed, processed for double 
immunoflourescence labeling with anti-AR (green) and anti-c-myc (red) antibodies and 
analysed by confocal microscopy. Scale bar: 10 gm. Solid arrows point to cells with nuclear 
AR pattern; dashed arrow points at cell with cytoplasmic AR pattern. C Quantitation of the 
amount of each of the variants in the nucleus shows a significant decrease of nuclear ARv567 
after dynein disruption. N values: M12-ARv567 Control: n=9; Dynamitin: n=18. M12-AR-V7 
Control: n=28; Dynamitin n=10. Two-tailed t-test with equal variances.
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Figure 3.12 Wild-type AR and ARv567 associate with dynein. Whole cell lysates (WCL) from 
HEK293T cells transiently transfected with GFP-tagged wild-type AR, ARv567 and AR-V7 
were immunoprecipitated with an anti-GFP antibody or control IgG and immunoblotted for 
the presence of dynein and AR.
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variant in the nucleus was calculated for control and dynamitin- 
overexpressing cells using MetaMorph image analysis software by creating a 
sum projection of all z-stacks imaged. Percentages were calculated from 
integrated pixel values from the sum projection and are shown in Figure 3.11 
C. The quantitation shows a significant decrease of ARv567 in the nucleus of 
dynamitin expressing cells as opposed to control cells. No change however, 
was seen in dynamitin-overexpressing M12-AR-V7 cells compared to control.
The confocal microscopy experiments suggest that the ARv567 and not 
AR-V7 variant, require the motor protein dynein in order to traffic to the 
nucleus. Therefore, a co-IP experiment was carried out in HEK293T cells 
transiently transfected with GFP-tagged wild-type AR, ARv567 or AR-V7 to 
determine whether they associate with dynein. The co-IP, carried out w ith an 
anti-GFP antibody and shown in Figure 3.12 revealed that both the wild-type 
AR and ARv567, but not AR-V7, associated with dynein confirming the 
results that show that both wild-type AR and ARv567 are microtubule- and 
dynein- dependent for their nuclear accumulation, whereas AR-V7 does not 
require dynein-assisted microtubule transport for its nuclear accumulation.
3.8 Determining the minimum AR-microtubule binding domain
In order to narrow down the minimum AR-microtubule binding domain, 
seven other AR truncation mutants were produced by PCR-based cloning in a 
similar way to the N- and C- terminus AR truncations. The truncations were 
designed to correspond to AR functional domains as well as to cover the 
entire C-terminus region, as follows: the AR DNA binding domain (aa 559- 
624), the hinge region (aa 625-663), the DNA binding domain plus the hinge 
region (aa 559-663) as well as amino acids 540-724, 540-558, 664-724 and 725- 
919.
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Figure 3.13 Sub-cloning of AR truncations I. A: AR truncations 540-724, DNA BD (559-624), 
DNA-hinge region (559-663) and the hinge region (625-663) were sub-cloned into a pEGFP-Cl 
vector and a 2% agarose gel was used to run the four different fragments to check for correct 
size (AR540-724: 555 bp; AR-DNA BD: 198 bp; AR-DNA-Hinge: 315 bp; AR-Hinge: 117 bp). B: 
The pEGFP-Cl vector and all inserts were double digested with EcoRI and BamHI for 3 hr at 
37°C (only the vector shown) and the vector treated with alkaline phosphatise for an 
additional hour at 37°C before being purified, ligated and transformed into DH5a competent 
cells. C: A diagnostic PCR was carried out on 8 colonies from each of the kanamycin-agar 
plates and run on a 2% agarose gel. A positive control for AR (0.5 gl of pEGFP-Cl) was 
included beside each truncation, as well as a negative control (colony from the background 
transformation plate). All clones were positive for AR and two from each truncation were 
sent for DNA sequencing for verification. L: 100 bp or 1 kb DNA ladder.
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Figure 3.14 Sub-cloning of AR truncations II. A: A second batch of cloning was performed to 
sub-clone two further AR truncations into a pEGFP-Cl vector. PCR products were run on a 
2% agarose gel to check for fragment size (AR540-558: 57 bp; AR664-724: 183 bp). B: The 
pEGFP-Cl vector and all inserts were double digested with EcoRI and BamHI for 3 hr at 37°C 
(only the vector shown) and the vector treated with alkaline phosphatise for an additional 
hour at 37°C before being purified, ligated and transformed into DH5a competent cells. C: A 
diagnostic PCR was carried out on 8 colonies from each of the kanamycin-agar plates and run 
on a 2% agarose gel. A positive control for AR (0.5 pi of pEGFP-Cl) was included beside 
truncation. All clones were positive for AR and two from each truncation were sent for DNA 
sequencing for verification. L: 100 bp or 1 kb DNA ladder.
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Figure 3.15 Sub-cloning of AR truncations III. A: A third batch of cloning was performed to 
sub-clone AR540-724 and AR725-919 into a p3xFLAG-CMV vector. PCR products were run 
on a 2% agarose gel to check for fragment size (AR540-724: 555 bp; AR725-919: 588 bp). B: The 
p3xFLAG-CMV vector and all inserts were double digested with EcoRV and BamHI for 3 hr 
at 37°C (only the vector shown) and the vector treated with alkaline phosphatise for an 
additional hour at 37°C before being purified, ligated and transformed into DH5a competent 
cells. C: A diagnostic PCR was carried out on 8 colonies from each of the ampicillin-agar 
plates and run on a 2% agarose gel. A positive control for AR (0.5 gl of p3xFLAG-CMV) was 
included beside truncation. All clones were positive for AR540-558 and all but one for AR725- 
919. Two positive clones from each truncation were sent for DNA sequencing for verification. 
L: 100 bp DNA ladder.
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These deletion mutants were subcloned into either a pEGFP-Cl w ith 
the exception of aa 540-724 and 725-919 mutants, which were subcloned into a 
p3XFLAG-CMV vector, as the GFP-tag gave rise to a protein of approximately 
50 kDa, which is also the size of tubulin, whose excess in the co-sedimentation 
assay made the detection of the truncated proteins very challenging. The 
cloning process, shown in Figures 3.13-3.15, was performed by sticky-end 
cloning of PCR products with primers specific to the sequences to be 
amplified designed to include restriction enzyme targets sites for EcoRI and 
BamHI for the inserts cloned into the pEGFP-Cl vector and EcoRV and 
BamHI for the inserts cloned into the p3xFLAG-CMV vector. The resulting 
PCR products (Figures 3.13-3.15 A) and the cloning vectors were digested 
with the corresponding enzymes to generate complementary ends (Figures 
3.13-3.15 B), which were then ligated, transformed into DH5a competent cells 
and plated on Kan-agar or Amp-agar plates. Colonies from each plate were 
picked and a diagnostic PCR was carried out with the same primers used for 
the amplification of each insert from the original plasmid, to confirm the size 
of the inserts (Figures 3.13-3.15 D). The sequence of each truncation was 
confirmed by DNA Sanger sequencing. Once the sequence of each truncation 
was confirmed, illustrated relative to the wild-type AR in Figure 3.16 A, a 
microtubule co-sedimentation assay was performed to determine which 
truncation has the most affinity for the micro tubule polymer. Each truncation 
was transiently transfected into HEK293T cells. These cells are frequently 
used to exogenously express target proteins since they have higher 
transfection efficiencies, which are desired when large amounts of protein are 
needed for protein-protein interaction studies. GFP-tagged wild-type AR was 
also transfected into the cells and included as a positive control for 
microtubule binding. Whole cell lysates were extracted from transfected cells, 
incubated with exogenous purified bovine brain tubulin protein in PEM
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Figure 3.16 Narrowing down the AR-microtubule binding site. A: Schematic representation 
of full-length AR along with the seven smaller AR deletion mutants. B: HEK293T cells were 
transfected with either GFP-tagged wild-type-AR, or each of the seven smaller truncations 
and subjected to a microtubule co-sedimentation assay. Briefly, a total of 1 mg of precleared 
cell extract (HSS) from the transfected cells was incubated for 30 minutes with 10 (iM 
exogenous purified bovine brain tubulin and subjected to a cycle of polymerisation with 20 
|iM paclitaxel at 37°C. The samples were centrifuged at 100,000 g to separate the microtubule 
polymers (WP) from the soluble tubulin dimers (WS), resolved by SDS-PAGE and 
immunoblotted for the presence of AR and tubulin. HSS: high speed supernatant; HSP: high 
speed pellet; WP: warm pellet; WS: warm supernatant. None of the smaller AR truncations 
displayed clear microtubule-binding properties, except for truncation 559-624 (DBD+hinge), 
which showed a clear shift from the WS fraction to the WP. Tubulin was found as 
microtubule polymers in the WP fraction.
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buffer and subjected to a cycle of polymerisation at 37°C in the presence of 20 
pM paclitaxel for 30 min. After centrifugation, the warm  pellet (WP) was 
separated from the warm supernatant (WS), resuspended in an equal volume 
of PEM buffer and sonicated. Equal volumes from each of the fractions were 
loaded onto adjacent wells of an SDS-PAGE, resolved and immunoblotted 
with antibodies against GFP, FLAG and tubulin.
The results from this experiment are shown in Figure 3.16 B. None of 
these smaller AR deletion mutants had the same affinity for the microtubule 
polymer as the wild-type AR (AR(wt). However, the AR 559-663, 
corresponding to the DNA BD plus the hinge region and containing the NLS, 
had an increased presence in the WP compared to the other truncations, 
indicating a preference of this portion of the AR for the microtubule polymer. 
Densitometry analysis of the amount of each AR truncation in the WP 
revealed that 40% of AR 559-663 cofractionated with microtubule polymers, 
whereas the WP amount for the other six AR truncations varied between 5- 
25%. On the other hand, it appears that the hinge region (aa 625-663) prevents 
the DNA BD (aa 559-624) from associating with microtubules, as both the 
DNA BD and hinge alone associate with the soluble tubulin fraction (WS) but 
together they preferentially associated with the polymer. This suggests that 
the microtubule-binding domain on the AR protein is located in this region. 
Furthermore, these results are consistent with the finding that showed that 
the C-terminus of AR is responsible for microtubule-binding and although an 
AR binding domain of a few amino acids was not identified, these results 
suggest that maximum microtubule association requires contribution from 
more than one region within the protein's C-terminus.
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Once thought to solely provide a structural framework for the cell, the microtubule cytoskeleton is now understood to be critical for processes 
such as cell movement, vesicle and organelle transport (Allan, 1995; Goodson 
et al, 1997) as well as mitosis (Jackson et al, 2007). Furthermore, it is also clear 
that microtubules are essential for the intracellular trafficking of viruses 
(Leopold and Pfister, 2006), protein complexes and transcription factors 
(Giannakakou et al, 2000; Carbonaro et al, 2012). In interphase cells, 
microtubules cover the entire area of the cell's cytoplasm, originating from the 
MTOC, right outside the nucleus, and extending all the way to the plasma 
membrane, providing ample surface for protein-protein interactions. In 
epithelial cells, microtubules display an inherent polarity having their slow- 
growing minus-end embedded in the MTOC and their fast-growing plus-end 
oriented towards the plasma membrane. This polarity is utilised by 
microtubule-based motor proteins, moving cargos either towards the nucleus 
(dynein) or towards the plasma membrane (kinesins), thereby, allowing for
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the directional flow of signal information within the cell, which ultimately 
dictates cell function (Gunderson and Cook, 1999; Asrih et al, 2011; Babich and 
Burkhardt, 2011). All of these qualities make microtubules centralised nodes 
of dynamic signalling pathways (Etienne-Manneville, 2010), which remain 
largely unexplored and their therapeutic potential unexploited. Moreover, 
drugs that disrupt the normal function of microtubules are likely to inhibit the 
function of protein association with microtubules as well as microtubule- 
dependent trafficking of these factors. Therefore, this would be detrimental 
for cell fate since the pathways that are needed for cell survival and that 
depend on microtubules would be irreversibly damaged. This makes 
microtubule-targeting drugs, specifically the taxanes, one of the most effective 
class of chemotherapeutics and their success in clinical oncology 
acknowledges that tubulin is one of the best drug targets identified to date. 
However, despite the presence of tubulin in all cancer cells, there are several 
solid tumour types that to not respond to taxane therapy, including colon 
cancer, renal cell carcinoma (RCC), pancreatic and liver cancer. Therefore, it is 
likely that the effect of taxanes is linked to the downstream pathways affected 
following microtubule disruption and not only mitosis.
In the case of prostate cancer, driven primarily by AR signalling, the 
disease has been traditionally treated with ADT. Although our understanding 
of the molecular basis of prostate cancer has significantly increased over the 
past decade, ADT for men who develop métastasés is still basically the same 
as first proposed 60 years ago -  interfere with androgen signalling (Huggins, 
1944) and nearly seven decades later, clinicians and researchers still struggle 
to completely understand the disease and optimise ADT. The goal of ADT is 
to block active AR signalling, either by eliminating the ligand or affecting the 
receptor directly. While most prostate cancer patients are initially sensitive to 
androgen withdrawal, loss of sensitivity to ADT occurs, leading to the
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development of CRPC (Massard and Fizazi, 2011). Similarly, even with the 
introduction of new and more effective therapies that target the androgen axis 
-such as the CYP17A1 inhibitor, abiraterone, which targets the central 
synthesis of testosterone and the AR-antagonist MDV3100- ADT is not 
curative (Massard and Fizazi, 2011). The molecular disturbances that 
contribute to prostate cancer progression in the setting of castrate levels of 
circulating androgen, have been extensively reviewed (Attard et al, 2011; 
Bryce and Ryan, 2012; Ryan and Tindall, 2011; Harris et al, 2009), but almost 
universally allow for the continued function of the AR as a transcription 
factor resulting in androgen-driven prostate cancer growth. Consequently, 
targeting the androgen axis has remained a key concept in the development of 
novel therapeutic strategies.
In 2004, the combination of docetaxel plus prednisone was established 
as the standard of care for first-line treatment of patients with CRPC, making 
taxanes the first class of chemotherapy drugs shown to improve survival in 
CRPC (Tannock et al, 2004; Petrylak et al, 2004). In addition, a novel taxane, 
cabazitaxel, was recently approved by the FDA as a second line 
chemotherapy in patients that previously failed docetaxel (de Bono et al, 
2010). However, despite promising clinical responses, the benefit of taxane 
chemotherapy in men with CRPC is transient and nearly all patients 
eventually progress. The primary mechanism of action of taxanes, inhibition 
of mitosis, has not helped us understand the molecular basis of clinical 
response and resistance to taxane chemotherapy, as this model applies 
primarily to rapidly dividing cells and tissues, which is not the case in 
patients' tumours. This raises the question of what are the functions of 
interphase microtubules that are critical for the growth and survival of the 
tumour?
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This study has been focused on analysing signalling pathways that 
depend on intact microtubules and whose disruption by taxane treatment 
would be fatal for tumour cell survival. This in turn will lead to a better 
understanding of the molecular basis of clinical response to taxane 
chemotherapy, which is imperative for establishing successful treatment of 
CRPC. Considering that AR signalling remains the main driver of disease and 
progression in CRPC patients despite prior anti-androgen therapies (Chen et 
al, 2004), the impact of tubulin and microtubule-targeting drugs was 
evaluated on AR signalling and trafficking. The results obtained provide 
evidence for a role of taxanes in prostate cancer interphase cells and suggest 
that interphase microtubule functions coupled with the trafficking and 
signalling pathways they regulate are indeed the effective targets of taxane 
treatment.
Microtubules have been shown to play a role in the nuclear 
accumulation of several cellular regulatory proteins including p53 in response 
to DNA damage (Giannakakou et al, 2000), and the hypoxia-inducible factor 1 
(HIF-la) (Carbonaro et al, 2012), representing indirect targets of taxane 
activity. In the case of HIF-la, its activity is tightly regulated by microtubule 
dynamics through microtubule-dependent mRNA trafficking to sites of active 
protein translation (Mabjeesh et al, 2003; Carbonaro et al, 2010). Interestingly, 
this mechanism does not apply to RCC where H IF-la regulation is 
independent of microtubules (Carbonaro et al, 2012). These results can 
potentially explain the lack of taxane clinical activity in RCC, while 
identification of the cellular factors that link HIF-la to microtubules and are 
missing or are deregulated in RCC can provide a new therapeutic strategy for 
the treatment of this disease.
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Additional proteins whose translocation is microtubule-dependent are 
the Rb (Roth et al, 2007), the GR (Harrell et al, 2004) and the PTHrP (Lam et al, 
2002). Furthermore, the molecular motor protein dynein, which facilitates 
movement along microtubules towards the nucleus, is also implicated in the 
movement of several of these proteins. Although the mechanistic details have 
not been established in each case, it is intriguing that these proteins known to 
exhibit microtubule-facilitated nuclear protein import, are all proteins for 
which the importance of nuclear localisation to their respective physiological 
roles in the nucleus to control cell proliferation is clearly established. It would 
appear that the ability to localise rapidly and efficiently in the nucleus 
facilitated by the action of microtubules and dynein, in addition to the more 
conventional nuclear targeting action of importins may be integral to this at 
particular stages of the cell cycle such as interphase.
Prompted by the established clinical activity of taxanes in CRPC 
together with the fact that AR continues to drive disease progression despite 
prior anti-androgen therapies (Chen et al, 2004), the role of tubulin and the 
impact of microtubule-targeting drugs on AR trafficking and signalling was 
investigated.
In prostate cancer, the results presented in this study show that taxane 
chemotherapy impairs AR nuclear localisation, which has shown in turn to 
inhibit subsequent transcriptional activation of ARE-containing target genes 
(Darshan et al, 2011). The results from this study provide a mechanistic insight 
for the clinical activity of taxanes in CRPC by revealing an unconventional 
link between a nuclear transcription factor and the chemomechanics of the 
microtubule cytoskeleton. As illustrated by the model proposed in Figure 4.1, 
AR associates with microtubules and is trafficked towards the nucleus with 
the aid of the minus-end-directed motor protein
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Figure 4.1 Proposed model of taxane mechanism of action in prostate cancer. This model 
represents a novel mechanism of action for taxanes in prostate cancer, which implicate this 
class of drugs in critical interphase cellular functions such as AR intracellular transport and 
signalling. In the model, AR associates with microtubules and translocates to the nucleus via 
the motor protein dynein. This transport is made possible due to the inherent polarity of 
microtubules, which is recognised by the minus-end-directed motor protein dynein, to 
transport cargoes toward the nucleus. Taxanes, which bind to and hyperstabilise 
microtubules, inhibit this trafficking and subsequently prevent AR from reaching the nucleus 
and activating target gens. This mechanism of action predicts that the combination of a taxane 
with an inhibitor of AR ligand synthesis (i.e. abiraterone) or with inhibitors of AR-ligand 
interaction (i.e. MDV3100) would be synergistic in the clinical setting as there will be 
inhibition of AR signalling by two different but converging pathways. Additionally, the 
model predicts that a small molecule inhibitor of dynein would similarly impair AR nuclear 
accumulation and would also be synergistic in combination with a taxane. Finally, the model 
suggests that a putative small molecule inhibitor targeting the interaction between AR and 
microtubules or dynein could be used therapeutically for CRPC treatment.
dynein. It is well established that upon ligand binding AR dimerises and the 
ligand-receptor complex translocates to the nucleus (Feldman and Feldman, 
2001). However, the mechanism enabling this translocation was previously 
unknown. Microtubules have been identified as the "highway tracks" that 
enable the rapid and targeted nuclear "delivery" of AR, which is required for 
its transcriptional activity. The critical function of dynein for the trafficking of 
wild-type AR as well as for the ARv567 variant has also been established.
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Furthermore, results from the in vitro microtubule binding assay (Figure 3.4) 
show that AR binds microtubules directly using in vitro recombinant AR 
protein and purified microtubule protein. This result suggests that AR has 
affinity for the microtubule network, possibly for the purpose of cytoplasmic 
tethering and that it becomes "released" from the microtubule and available 
for trafficking following ligand stimulation. In support of this model, the 
results in Figure 3.3 C showed that upon ligand binding the association of AR 
with microtubules is diminished while the association of AR with dynein is 
enhanced (Darshan et al, 2011). This model also raises the question of what 
other function might AR tethered to microtubules have?
A potential function could be that of a microtubule associated protein 
that could modulate endogenous microtubule properties such as microtubule 
stability and dynamicity. Such role has been demonstrated for the von 
Hippel-Lindau (VHL) tumour suppressor gene, whose protein (pVHL) has 
been shown to bind microtubules and protect them from depolymerisation 
upon treatment of cells with the microtubule depolymerising drug, 
nocodazole (Hergovich et al, 2003). pVHL acts as an E3 ubiquitin ligase for 
H IF-la degradation in normoxic conditions (Maxwell et al, 1999; Cockman et 
al, 2000). In hypoxic conditions, typically found in tumour 
microenvironments, H IF-la is stabilised and induces angiogenesis, necessary 
for tumour growth. Mutations in VHL result in VHL disease, a rare genetic 
condition that predisposes individuals to tumours of the eye and central 
nervous system. Furthermore, mutations in VHL are associated with a high 
risk of RCC, which is known to have a deregulation of H IF-la (Kamura et al, 
2000; Ohh et al, 2000; Cockman et al, 2000). The microtubule-stabilising 
function of pVHL, independent of its function as an E3 ubiquitin ligase, has 
been linked to its role in the maintenance of cilia, protection from kidney cyst 
formation and the suppression of spindle misformation (Schermer et al, 2006;
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Frew et al, 2008; Thoma et al, 2009). The microtubule-binding and stabilising 
functions of pVHL require specific residues contained within amino acids 95- 
123, and are disrupted by specific point mutations in amino acids 98 and 112 
(Hergovich et al, 2003). Additionally, it has been found that different naturally 
occurring VHL mutants have different abilities amongst each other to regulate 
microtubule dynamic instability such as inhibiting catastrophe and enhancing 
rescue events (Thoma et al, 2010).
Along these lines, it is possible that the different AR splice variants that 
exhibit differential association patterns with cellular microtubules, could be 
affecting microtubule dynamic stability parameters in a way that could also 
affect cell sensitivity to microtubule inhibitors. Another possibility is that AR 
associates with microtubules in order to interact with other protein partners 
and initiate downstream signalling or that AR becomes "protected" from 
proteosome degradation while it remains attached to microtubules. In vitro 
studies using recombinant AR protein, recombinant AR splice variants and 
purified microtubules are required to further investigate AR binding affinity 
to microtubules as well as potential effects of AR on microtubule 
conformation with more sophisticated cryo-electron microscopy studies.
The recently identified AR splice variants ARv567 and AR-V7 have 
been postulated to cause progression of prostate tumours after castration. 
ARv567 has been shown to form a complex with full-length AR (Sun et al, 
2010) and is able to alter the expression of androgen-regulated genes such as 
PSA, TMPRSS2 and NKX3.1, presumably through its interaction with the 
wild-type receptor. However it is unknown whether these variants are also 
capable of activating canonical AR regulated genes in the absence of wild- 
type AR signalling. In addition, the expression of AR splice variants increases 
acutely in response to androgen withdrawal and is suppressed by
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testosterone (Watson et al, 2010). Therefore, since these data indicate that the 
increase in AR splice variant expression in CRPC is an acute response to 
castration and given that ARv567 is not expressed in the nucleus of normal 
prostate epithelium or at substantial levels in primary prostate cancer, a two 
way feedback between the full-length AR and the ARv567 could be proposed 
in which the variant induces full-length AR and in turn full-length AR 
reduces expression of the variant. Castration would appear to induce the 
variant by inhibiting the full-length AR from repressing it; therefore, the 
variant would become overexpressed. Interestingly, in mouse xenograft 
models, the LuCaP 86.2 xenograft (derived from CRPC patients after ADT 
therapy), which has the majority of its AR in the ARv567 form, has no 
castration response, but appears to be sensitive to microtubule control as 
measured by the decrease in tumour volume in mice after taxane treatment 
(unpublished data from Stephen Plymate). In contrast, the LuCaP 70 
xenograft, with low levels of ARv567, responded very well to castration but 
was not as sensitive to docetaxel. Also, the LuCaP 23, which expresses wild- 
type AR as well as AR-V7, was shown in the same experiments to not be as 
sensitive to taxane treatment, responding only to high doses of docetaxel. 
These data together with the results showing that ARv567, but not AR-V7, 
associates with microtubules and its accumulation is dynein-dependent could 
serve as a useful biomarker of taxane clinical response in CRPC as it can be 
predicted that patients harbouring the ARv567 would respond better to 
taxane therapy than those expressing a majority of AR-V7.
One major caveat of the live cell imaging studies done on both variants 
and presented in Figures 3.9 and 3.10 is that no actual trafficking of either 
variant was visualised, instead just the effect of microtubule-targeting drugs 
at timepoint 0. This is because, as soon as enough GFP was expressed by the 
microinjected cells to be detected by eye under the microscope, the GFP-
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tagged variants were already found in the nucleus, unlike the wild-type AR, 
and thus it was impossible to catch them in the cytoplasm before their 
extremely fast translocation. This is in part due to the limitations of the 
microscopy technology which requires minimum amounts of fluorescent 
protein levels to be imaged. So, as soon as the variant proteins were made, 
they translocated to the nucleus, before they could be visualised. However, 
the effects of docetaxel and nocodazole on this rapid nuclear localisation were 
evident since they clearly affected the rate of trafficking of ARv567 at 
timepoint 0. It was possible to determine their effects on variant trafficking 
since the drugs were added to the cells right after they had been 
microinjected, without giving enough time for protein expression and 
subsequent nuclear translocation to occur, but still being able to affect 
microtubules by the time this was apparent.
The model presented in Figure 4.1 provides a basis for understanding 
clinical taxane resistance in prostate cancer. Binding of taxanes to ^-tubulin, 
suppresses microtubule dynamics and hyper-stabilises the microtubule 
cytoskeleton by inducing the formation of microtubule bundles; a hallmark of 
effective drug-target engagement. Microtubule bundling is the first cellular 
insult that leads to disruption of downstream pathways. This mechanism 
implies that taxane chemotherapy should be most effective against tum our 
types in which microtubule-dependent pathways drive tumour progression, 
like the AR pathway in prostate cancer. Furthermore, the findings also 
suggest that patients responding to taxane-based chemotherapy have an 
intact microtubule-AR axis for maximum activity, such that if a patients' 
tumour harbours tubulin mutations at the drug's binding site or AR 
alterations that render the receptor independent of microtubule control, then 
the ability of the taxanes to effectively inhibit the axis will be compromised 
leading to drug resistance. Further evidence that the perturbation of the
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microtubule-AR axis is an important determinant of taxane activity 
independent of mitosis, was shown by the AR cytoplasmic sequestration 
observed in circulating tumour cells isolated from CRPC patients, which 
significantly correlated with clinical response to taxane chemotherapy 
(Darshan et al, 2011).
Despite the success of taxanes in CRPC treatment, their efficacy varies 
from patient to patient while it remains unclear why individual patients 
respond to paclitaxel but not docetaxel and vice versa, even though these 
drugs share the same mechanism of action and a common binding site on 13- 
tubulin. This could be due to a mutation of a certain residue that can confer 
resistance to one, but not another microtubule-stabilising drug. This concept 
has been shown in the paclitaxel-resistant cell line PTX10, derived from the 
parental ovarian cancer cell line 1A9, where AR was exogenously expressed 
and where taxane-induced AR cytoplasmic sequestration occurred 
downstream of taxane-induced microtubule stabilisation (Darshan et al, 2011). 
PTX10 cells have an acquired mutation in (3-tubulin at position 270 that 
confers a 20-fold resistance to PTX treatment over parental cells (Giannakakou 
et al, 1997). Taxane treatment had no effect on AR subcellular localisation in 
PTX10 cells consistent with the drug's inability to stabilise microtubules; 
whereas, the DHT-induced AR nuclear accumulation was robustly inhibited 
by taxane treatment in the 1A9 parental cells. These results substantiate the 
importance of understanding the lack of cross-resistance between different 
therapies by identifying tubulin mutations in patients as well as the 
downstream pathways that are affected by hitting interphase microtubules. 
The FDA approval of the docetaxel-analogue cabazitaxel for the treatment of 
CRPC patients who have previously failed docetaxel-based therapy (de Bono 
et al, 2010) highlights, once again, the activity of this class of drugs in CRPC 
while raising the question of what is the molecular basis of clinical taxane
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resistance. According to the model, clinical taxane resistance could arise as a 
result of: 1) impaired drug uptake, potentially due to the presence of P- 
glycoprotein (P-gp) or other drug transporters; 2) impaired binding to 13- 
tubulin, possibly due to the presence of tubulin mutations at the drug binding 
site or overexpression of (3III tubulin isotype; 3) presence of AR mutations or 
splice variants that do not require microtubule-based transport; and 4) 
dysregulation of dynein-cargo interaction.
Regarding the first possibility, limited studies have not suggested a 
significant correlation between P-gp expression and response to taxane 
treatment in prostate cancer patients (Hamidovic et al, 2010). Similarly, 
tubulin alterations such as (3-tubulin mutations or altered isotype expression, 
have not been associated with response to taxane-based therapy in CRPC 
either (Kavallaris, 2010). Conversely, alterations of AR have been extensively 
studied in CRPC albeit not in the context of taxane resistance. Recent studies 
have demonstrated the presence of alternatively spliced AR variants, such as 
ARv567 and AR-V7 that arise following castration (Hu et al, 2009; Guo et al, 
2009; Sun et al, 2010; Watson et al, 2010). These variants that lack the LED, are 
insensitive to ADT and are constitutively active in the nucleus, which allows 
for continuous AR transcriptional activity. The ARv567 variant was shown to 
be present in 59% of CRPC patients and to arise in response to ADT or to the 
newer AR-targeted therapies, such as abiraterone (Mostaghel et al, 2011). The 
frequency of this molecular alteration in CRPC makes it imperative to 
determine whether these variants would respond to taxane treatment in 
patients. This model predicts that any AR variant lacking the microtubule- or 
dynein-binding domain would be insensitive to taxane treatment and thereby, 
has the potential to serve as a predictive biomarker of clinical taxane activity. 
The results show indeed that AR-V7 does not respond to taxane treatment, 
unlike ARv567. Interestingly, AR-V7 lacks the AR NTS, located in the hinge
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region of the receptor, a region which is necessary to allow the binding of AR 
to microtubules as seen by the association of the DNA BD-Hinge region to the 
microtubule (Figure 3.16 B). The association to the microtubule polymer was 
notably reduced by the DNA BD and the hinge region individually compared 
to the two together. Thus, this could explain why AR-V7 is not affected by 
microtubule-targeting drugs, since it lacks the putative AR-microtubule 
binding site. Nevertheless, the AR mutagenesis approach carried out to 
determine which portion of AR binds to microtubules does not take into 
account any potential contributions from the N-terminal region, or any other 
region, to the overall structure of the receptor bound to microtubules. It is 
possible that the putative microtubule domain on the AR is a result of more 
than one region of the AR folding together to give the correct 3D 
conformation for the binding to occur. This concept would be better tested 
with an approach that directly examines the structure of the wild-type AR or 
AR variants such as electron crystallography. Finally, regarding the 
dysregulation of dynein-cargo interaction, the model predicts that any 
aberration/m utation in the dynein motor protein that impairs cargo (AR) 
recognition an d / or transport should lead to taxane resistance.
In accordance with data that shows that AR interacts with dynein, and 
other data showing that AR is imported through the classical imp or tin 
pathway (Cutress et al, 2008), a microtubule-assisted nuclear import that 
occurs through interactions with the NTS of the cargo and dynein could be 
proposed. The NLS would employ the dynein motor complex to traffic along 
the microtubules to the nucleus, where imp or tin proteins are able to recognise 
the NLS and mediate import through the nuclear pore complex (NPC) (Figure 
4.2). In terms of the rapid trafficking of the variants to the nucleus, it is 
foreseeable that AR-V7 might lack the putative microtubule binding domain
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Figure 4.2 Microtubule-assisted nuclear import. Conventional nuclear import involves 
proteins containing an NLS being recognised by importin a /p  and being translocated 
through the NPC assisted by a RanGTP/GDP cycle, with nuclear export occurring in a similar 
fashion (steps 1-5). Microtubule-assisted import occurs when NLS containing proteins are 
able to bind dynein, which then traffics along the microtubule and brings the cargo in 
proximity to the importins and the NPC (steps 6-7) (Wagstaff and Jans, 2009).
(part of it located in the hinge region of the receptor) that tethers the full- 
length AR to the cytoplasm. This conformation of the variant might expose its 
dynein binding domain permanently, allowing its continuous trafficking to 
the nucleus where it would use the same domain to bind DNA.
The results presented in this study provide evidence that the clinical 
activity of taxanes in prostate cancer can be attributed in part to the inhibition 
of AR activity via its effect on microtubules and that simultaneous targeting 
of different pathways that inhibit AR signalling, may result in greater or more 
durable anti-tumour effects. Specifically, combination of a taxane, which 
interferes with AR nuclear translocation, with an inhibitor of androgen
113
Discussion
synthesis (e.g. abiraterone) or an inhibitor of AR-ligand interaction such as 
MDV3100, which also inhibits AR nuclear accumulation (by yet an undefined 
mechanism) (Tran et al, 2009), could yield enhanced therapeutic efficacy. To 
this end, a Phase I trial is currently testing the combination of docetaxel and 
abiraterone in patients with CRPC.
More importantly, understanding the precise mechanisms by which 
prostate cancer cells circumvent AR signalling inhibition will allow 
development of novel, more targeted therapies. For instance, the development 
of a small molecule inhibitor of dynein, or of dynein-AR interaction could be 
added to the space of CRPC therapy. Similarly, the recent identification of an 
N-terminal-targeted AR inhibitor which has the potential to target both AR 
wild-type and variants, as the N-terminal domain is conserved (Andersen et 
al, 2010; Sadar, 2011) should be synergistic in combination with a taxane.
A deeper understanding of the mechanisms used by a prostate cancer 
cell to bypass AR inhibition as well as the cellular factors that regulate AR 
signalling in CRPC is required in order to develop approaches that will allow 
men to live with metastatic prostate cancer beyond the 1-2 years typically 
associated with responses to chemotherapy after ADT.
Future studies to continue to tackle the AR-microtubule axis would include a more precise elucidation of the minimum AR-microtubule 
binding domain. This would be done by cryo-electron microscopy studies that 
would determine the crystal structure of the AR bound to the microtubule. 
However, the rate-limiting step of these experiments would be obtaining 
sufficient quantities of recombinant AR protein, which would have to be 
expressed in an insect cell system, known for not producing large yields of 
purified protein.
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The effects of each variant on microtubule dynamics would be studied 
on prostate cancer cell lines stably expressing the variants using a well known 
microtubule tip-tracking protein, EB1, which would provide information on 
the rate of microtubule growth and shrinkage.
The rate of the AR splice variants nuclear localisation would be more 
closely studied with the use of speckle fluorescent microscopy, a method 
originally developed for measuring the movements and dynamic assembly of 
macromolecular structures such as cytoskeletal filaments (e.g. microtubules 
and actin) or focal adhesions. This technique would require AR to be 
expressed in a "reduced-expression GFP plasmid" to obtain minimum 
amounts of GFP-AR-variant that appear as a "speckle", therefore allowing to 
be tracked as close to single molecules as possible.
It is imperative to discern the gene signatures induced by each variant 
and whether they could contain genes known to regulate endogenous 
microtubule dynamics such as O pl8/  stathmin and other MAPs since 
induction or repression of these genes could indirectly modify endogenous 
microtubule behaviour ultimately affecting sensitivity to microtubule 
inhibitors.
It will be of great interest to continue to determine the sensitivity of the 
AR variants to taxanes in xenograft models of CRPC. These variants could 
provide a valuable biomarker for prediction of treatment success and have an 
enormous impact on the development of improved targeted therapies in 
addition to a better selection of patients more likely to benefit from 
microtubule-targeting therapies.
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Sum m ary
Despite the success of taxane-based chemotherapy, treatment efficacy varies from patient to patient and even in responsive patients, the 
therapeutic benefit of taxane treatment cannot be indefinitely sustained. 
Currently, no study has identified the mechanisms underlying taxane activity 
in prostate cancer. The work presented in this study challenges the existing 
paradigm whereby the clinical activity of taxanes are attributed to the drug's 
antimitotic effects and not to the downstream signalling pathways occurring 
on interphase microtubules that essential for tumour survival and progression 
and that are disrupted as a result of the microtubule cytoskeleton disruption. 
Understanding the role of microtubules in AR nuclear accumulation and 
signalling, how taxane therapy disrupts these pathways, and what 
mechanisms allow for continued AR signalling in CRPC, through the 
appearance of AR splice variants will have an enormous impact on the 
development of improved targeted therapies in addition to a better selection 
of patients more likely to benefit from microtubule-targeting therapies.
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Simultaneously these results will lead to enhanced survival rates and an 
improved quality of life, by reducing debilitating side effects and illness from 
CRPC patients.
Beyond the clinical outcomes, this study identifies a novel mechanism 
for taxane activity in prostate cancer by illustrating a novel role for 
microtubules in the regulation of AR signalling and trafficking, thus 
advancing the field of CRPC with important implications for enhanced 
molecular therapy for CRPC patients.
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